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   My favorite definition of Internal Medicine is “the Medicine of complexity”: complexity 
in quantity, in patients with multiple concomitant diseases, whose management must 
be plural; and complexity in quality, in patients with poorly known clinical conditions, 
who need both a wise knowledge and a meticulous regard, as well as perseverance 
on diagnosis pursuance, optimally developed by internist’s endeavor. 
   Systemic sclerosis is a prototype of the latter and has soon triggered my inquisitive 
concern. The disease constitutes a fair example of how multiple organ systems link, 
interact and cause disease, reinforcing the role of a holistic approach. 
 
“With research, possibilities are limitless. Be part of the change.” 
 
Slogan of Rare Disease Day 2017 
 
 
   Researching is intrinsic to the curious internist, who recognizes that the whole one 
can know is still scarce. I believe that every tiny discover is a further cobblestone on 
human path to knowledge. And the most valuable learnings reside on the journey, 
rather than on the end.  
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Thesis Outline 
 
   In Chapter I. Introduction, a review of the literature will be presented, including an 
overview of systemic sclerosis and very early diagnosis of systemic sclerosis, focusing 
on the currently known pathogenesis of systemic sclerosis microvasculopathy. This 
chapter will also comprise the review paper: 
• First Paper – Chora I, et al. “Vascular biomarkers and correlation with 
peripheral vasculopathy in systemic sclerosis.” Autoimmun Rev. 2015 
Apr;14(4):314-22. 
   Reference will be made to a recently published Commentary, that will be available 
at the Appendix: 
• Fourth Paper – Matucci-Cerinic M, Manetti M, Bruni C, Chora I, et al. “The 
‘myth’ of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic 
process or just a late unavoidable event?” Arthritis Res Ther. 2017 Jul 
6;19(1):162. 
   In Chapter II. Aims, the main objectives of the study will be pointed out. 
   In Chapter III. Methods, the study design and methodology will be succinctly 
introduced. 
   Chapter IV. Results will present the papers reporting the findings of the study: 
• Second Paper – Romano E, Chora I, et al. “Decreased expression of 
neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy 
and defective angiogenesis in systemic sclerosis.” Ann Rheum Dis 
2016;75:1541-1549. 
• Third Paper – Chora I, et al. “Evidence for a Derangement of the Microvascular 
System in Patients with a Very Early Diagnosis of Systemic Sclerosis.” J 
Rheumatol. 2017 Aug;44(8):1190-1197. 
   Chapter V. General Discussion will debate and summarize the importance of the 
results described in this project. 
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   Chapter VI. Conclusions and Future Perspectives will highlight the main 
contribution of these findings to the state of the art in systemic sclerosis pathogenic 
views and raise further concerns for future research. 
   The References will be enumerated at the end of the document. 
   An Appendix containing the fourth paper and other supplementary files will be 
provided. These documents will be denoted in the text as [Doc. ]. 
  
XVII 
 
List of Figures 
 
Figure 1 – Main cornerstones in the pathogenesis of systemic sclerosis. …………....12 
Figure 2 – Synthesis of systemic sclerosis pathogenesis……………………………....22 
Figure 3 – Progression of systemic sclerosis. ……………………………………….….29 
Figure 4 – The potential mechanism of SSc vasculopathy leading to tissue fibrosis. 33 
Figure 5 – Potential mechanisms of deregulated angiogenesis in SSc. ……………...50 
Figure 6 – The significance of “time” in systemic sclerosis. ………………………..…..52 
Figure 7 – VEGF family. …………………………………………………………………...54 
Figure 8 – Neuropilin structure and hypothetical model of interaction with multiple 
growth factors. ………………………………………………………………………..…….56 
Figure 9 – Crosstalk between NRP ligands. ………………………………..….………..57 
Figure 10 – Current pathogenic views of disturbed angiogenesis in systemic sclerosis. 
………………………………………………………………………………………………113 
 
  
XVIII 
 
List of Tables 
 
Table 1 – The American College of Rheumatology/European League Against 
Rheumatism criteria for the classification of systemic sclerosis. ……………………….23 
Table 2 – Criteria of classification of diffuse and limited cutaneous SSc according to 
LeRoy et al. …………………………………………………………………………………24 
Table 3 – Main clinical manifestations of SSc. …………………………………………..25 
Table 4 – Chronogram of PhD Activities. …………………………………………..…….69 
Table 5 – Inclusion and exclusion criteria for study participants. ……………...……….70 
Table 6 – Demographic and clinical characteristics of the patients with SSc and 
VEDOSS included for collection of serum samples. …………………………………….71 
  
XIX 
 
List of Acronyms 
 
ACA – anticentromere antibodies 
ANA – antinuclear antibodies 
AOUC – Azienda Ospedaliero-Universitaria Careggi 
CHSJ – Centro Hospitalar de São João 
CTGF – connective tissue growth factor 
dcSSc – diffuse cutaneous systemic sclerosis 
ECs – endothelial cells 
ECM – extracellular matrix 
EPC – endothelial progenitor cell 
ET-1 – endothelin 1 
EULAR – European League Against Rheumatism 
EUSTAR – European League Against Rheumatism Scleroderma Trials and Research 
Fli1 – Friend leukaemia integration 1 
H-MVECs – healthy microvascular endothelial cells 
IL – interleukin 
lcSSc – limited cutaneous systemic sclerosis 
MVECs – microvascular endothelial cells 
NRP1 – neuropilin 1 
NRPs – neuropilins 
NVC – nailfold videocapillaroscopy 
PAH – pulmonary arterial hypertension 
PDGF – platelet-derived growth factor 
RNA – ribonucleic acid 
RP – Raynaud’s phenomenon 
Sema3 – class 3 semaphorins 
Sema3A – semaphorin 3A 
SSc – systemic sclerosis 
TGF-β – transforming growth factor-beta 
uPAR – urokinase-type plasminogen activator receptor 
VEDOSS – very early diagnosis of systemic sclerosis 
VEGF – vascular endothelial growth factor 
VEGFRs – vascular endothelial growth factor receptors 
vSMCs – vascular smooth muscle cells  
XX 
 
 
1 | Abstract/Resumo 
 
I. ABSTRACT/RESUMO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Paul Klee. Abstraction with Reference 
to a Flowering Tree (1925). 
2 
 
 
  
3 | Abstract/Resumo 
 
Abstract 
   Systemic sclerosis (SSc) is a rare and heterogeneous autoimmune disorder of 
unknown etiology, characterized by widespread vascular injury and dysfunction, 
impaired angiogenesis, immune deregulation and progressive ﬁbrosis of the skin and 
internal organs. 
   SSc is typically diagnosed late. The establishment of preliminary criteria for very 
early diagnosis of systemic sclerosis (VEDOSS) (Raynaud's phenomenon [RP] and 
puffy fingers, together with abnormal nailfold videocapillaroscopy and positive SSc-
specific antinuclear antibodies) intend to counteract this tendency, as earlier 
identification and treatment of VEDOSS patients may slow disease progression. 
   A growing body of evidence supports the concept that SSc is primarily a vascular 
disease, mediated by autoimmunity and evolving into tissue ﬁbrosis. The deregulation 
of vascular tone control, clinically evident as RP, and microcirculatory abnormalities 
are the earliest clinical manifestations of SSc and may precede cutaneous and visceral 
involvement by months or years. 
   Despite the hypoxic conditions of microangiopathy, angiogenesis is paradoxically 
impaired in SSc. It has been shown that vascular endothelial growth factor (VEGF)-
A/VEGF receptor (VEGFR) signaling pathway is profoundly disturbed in SSc, namely 
due to a switch into VEGF-A165 anti-angiogenic isoforms. Altered expression of 
neuropilin 1 (NRP1), a receptor for both class 3 semaphorins and VEGF-A, might play 
a role on this process and had not been studied in SSc, to the date of this project 
writing. 
     The aim of the thesis was to explore the microvasculopathy and deregulated 
angiogenesis, namely the possible involvement of the axis NRP1/semaphorin 3A 
(Sema3A), in 55 SSc patients and 25 VEDOSS patients from two hospital centers. 
   Serum circulating levels of Sema3A and soluble NRP1 (sNRP1) were measured by 
enzyme-linked immunosorbent assay (ELISA). NRP1 and Sema3A expression in skin 
biopsies was evaluated by immunoﬂuorescence and Western blot. NRP1 expression 
was assessed in dermal microvascular endothelial cells (MVECs) of SSc (SSc-
MVECs) and healthy controls, in endothelial progenitor cell (EPC)-derived endothelial 
cells (ECs) of SSc and controls and in healthy MVECs (H-MVECs) stimulated with 
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patients’ sera, by Western blot. The possible impact of transcription factor Friend 
leukaemia integration 1 (Fli1) deﬁciency on endothelial NRP1 expression was 
investigated by gene silencing. The binding of Fli1 to NRP1 gene promoter was 
evaluated using chromatin immunoprecipitation. Capillary morphogenesis was 
performed on Matrigel. Cell proliferation was assessed by 5’-bromodeoxyuridine assay 
and migration capacity by in vitro wound-healing assay. 
   Serum levels of pan-VEGF were increased in SSc and VEDOSS patients versus 
controls, while serum levels of sNRP1 were signiﬁcantly reduced in those patients, 
compared to controls. In SSc, decreased sNRP1 levels were associated with “active” 
and “late” nailfold videocapillaroscopy patterns and digital ulcers. 
   NRP1 expression was constitutively downregulated in SSc-MVECs, both ex vivo and 
in vitro, but not in SSc peripheral blood EPC-derived ECs. The expression of NRP1 
was signiﬁcantly reduced in H-MVECs after treatment with patients’ sera, being 
upregulated after stimulation with recombinant VEGF-A165. 
   No differences were found for Sema3A serum levels or expression between patients 
and controls. 
   Fli1 was signiﬁcantly decreased in H-MVECs challenged with SSc sera, but not in 
SSc EPC-derived ECs. Fli1 occupied the NRP1 gene promoter and Fli1 gene silencing 
reduced NRP1 expression in H-MVECs. NRP1 gene silencing in H-MVECs resulted in 
a signiﬁcantly impaired angiogenic capacity, comparable to that of cells treated with 
SSc sera. 
   Capillarogenesis, migration and proliferation were decreased in H-MVECs 
stimulated with SSc and VEDOSS sera, compared to cells stimulated with healthy 
sera. 
   In conclusion, NRP1 deﬁciency may be an additional factor in the perturbed VEGF-
A/VEGFR-2 signaling, contributing to peripheral microvasculopathy and defective 
angiogenesis in SSc, which are evident from the very early stage of the disease. 
 
Key-words: systemic sclerosis; very early diagnosis of systemic sclerosis; 
angiogenesis; biological markers. 
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Resumo 
   A esclerose sistémica (SSc) é uma doença autoimune rara e heterogénea, de 
etiologia desconhecida, caracterizada por lesão e disfunção vasculares, desregulação 
imune e fibrose progressiva cutânea e visceral. 
   O diagnóstico de SSc é habitualmente tardio. Os critérios preliminares para 
diagnóstico muito precoce de esclerose sistémica (VEDOSS) (fenómeno de Raynaud 
[RP] e edema digital, com alterações capilaroscópicas e anticorpos antinucleares 
específicos de SSc positivos) pretendem contrariar esta tendência, uma vez que a 
identificação e tratamento precoce dos doentes com VEDOSS poderão retardar a 
progressão da doença. 
   Evidência científica crescente sugere que o atingimento vascular é o evento 
patogénico primário na SSc, mediado por fenómenos de autoimunidade e progredindo 
posteriormente para fibrose tecidular. A disfunção do tónus vascular, evidente no RP, 
e as alterações da microcirculação são as manifestações clínicas mais precoces de 
SSc e podem preceder o envolvimento cutâneo e visceral por meses a anos. 
   Apesar da hipóxia determinada pela microangiopatia, a angiogénese encontra-se 
paradoxalmente comprometida na SSc. A desregulação da via de sinalização do fator 
de crescimento endotelial vascular (VEGF)-A e seu recetor (VEGFR) tem implicações 
importantes neste paradoxo, nomeadamente pela sobre-expressão da isoforma anti-
angiogénica do VEGF-A165. O possível envolvimento da neuropilina 1 (NRP1), recetor 
quer da classe 3 das semaforinas quer do VEGF-A, constituía uma lacuna de 
investigação na patogénese da SSc, até à data do presente trabalho. 
   O objetivo da tese consistiu em explorar a microvasculopatia e a angiogénese 
desregulada, nomeadamente o possível envolvimento do eixo NRP1/semaforina 3A 
(Sema3A), em 55 doentes com SSc e 25 doentes com VEDOSS, seguidos em dois 
centros hospitalares. 
   Os níveis séricos de Sema3A e NRP1 solúvel (sNRP1) foram medidos por ELISA. 
A expressão de NRP1 e Sema3A em biópsias cutâneas foi avaliada por 
imunofluorescência e Western blot. A expressão de NRP1 foi avaliada em células 
endoteliais microvasculares (MVECs) cutâneas de SSc (SSc-MVECs) e de controlos 
saudáveis, em células endoteliais (ECs) derivadas de células progenitoras endoteliais 
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(EPC) e em MVECs saudáveis (H-MVECs) estimuladas com soros de doentes, por 
Western blot. O possível impacto do défice do fator de transcrição Friend leukaemia 
integration 1 (Fli1) na expressão endotelial de NRP1 foi investigado por silenciamento 
de genes. A ligação do Fli1 ao promotor do gene da NRP1 foi avaliada utilizando a 
técnica de imunoprecipitação da cromatina. A capilarogénese foi avaliada através do 
ensaio de formação de capilares em Matrigel. A proliferação celular foi avaliada pelo 
ensaio de incorporação de 5’-bromodeoxiuridina e a migração pela capacidade de 
cicatrização de cultura danificada. 
   Os níveis séricos de VEGF total estavam aumentados nos doentes com SSc e 
VEDOSS versus controlos saudáveis, enquanto que os níveis séricos de sNRP1 se 
encontravam significativamente reduzidos nesses doentes, comparados com os 
controlos. Na SSc, a diminuição de sNRP1 associou-se aos padrões capilaroscópicos 
“ativo” e “tardio” e à presença de úlceras digitais. 
   A expressão de NRP1 estava constitutivamente diminuída nas SSc-MVECs, ex vivo 
e in vitro, mas não em ECs derivadas de EPC de SSc. A expressão de NRP1 foi 
significativamente reduzida após estimulação das H-MVECs com soros de doentes, e 
sobre-regulada após estimulação com VEGF-A165 recombinante. 
   Não se registaram diferenças nos níveis séricos e expressão de Sema3A entre 
doentes e controlos. 
   O Fli1 encontrava-se significativamente diminuído nas H-MVECs estimuladas com 
soro de SSc mas não em ECs derivadas de EPC de SSc. O Fli1 ligou-se ao promotor 
do gene da NRP1 e o seu silenciamento reduziu a expressão de NRP1 nas H-MVECs. 
O silenciamento da NRP1 resultou no compromisso da capacidade de angiogénese 
das H-MVECs, comparável ao das células estimuladas com soro de SSc. 
   A capilarogénese, migração e proliferação encontravam-se diminuídas nas H-
MVECs estimuladas com soros de SSc e VEDOSS, em comparação com células 
estimuladas com soro saudável. 
   Em conclusão, o défice de NRP1 parece ser um fator patogénico adicional na via de 
transdução de sinal do VEGF-A/VEGFR-2, contribuindo para a microvasculopatia e 
comprometimento da angiogénese na SSc, evidentes desde a fase muito precoce da 
doença. 
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1. Systemic Sclerosis 
 
1.1 Definition and Epidemiology 
 
   Systemic sclerosis (SSc, previously known as scleroderma) (ORPHA90291) is a rare 
systemic autoimmune connective tissue disorder. This complex chronic illness has 
substantial interindividual variability in clinical manifestations and outcomes (1). SSc 
has long represented one of the greatest challenges on the management of 
autoimmune rheumatic diseases. Due to its unpredictable course and resistance to 
therapy, SSc has the highest disease-related mortality and morbidity (2, 3). 
   SSc is characterized by widespread vascular dysfunction and injury, immunological 
abnormalities and excessive extracellular matrix (ECM) accumulation. The most 
apparent and almost universal clinical features of SSc are related to the progressive 
fibrosis of the skin, the microvasculature and of numerous internal organs (4).  
   SSc has a prevalence of 5-24:100 000 and an incidence of 1-5:100 000, varying 
significantly in different geographic areas and time points (5, 6). There is a trend 
towards increasing prevalence and incidence rates in more recent studies (6). 
   In the European League Against Rheumatism Scleroderma Trials and Research 
(EUSTAR) register on 9149 SSc patients, the female/male sex ratio was 6:1 (7). The 
peak incidence lies between the third and fifth decades  and the age at disease onset 
differs according to gender and ethnic background (5, 6). Multiple studies have 
suggested that subjects of African ancestry have a higher susceptibility to SSc and 
develop more severe disease (6). 
 
 
1.2 Pathogenesis 
 
   The etiology of SSc remains largely unknown but is likely to involve the interaction 
of environmental factors in a genetically primed individual, under a regulatory 
epigenetic mechanism (8-12). Generation of mouse models allowed the identification 
of the main players in different phases of the pathophysiology (13). SSc is 
characterized by three cardinal pathogenic features: 1) microvascular endothelial 
cell/small vessel fibroproliferative vasculopathy, 2) immune system abnormalities and 
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3) connective tissue-producing cells (namely fibroblasts/ myofibroblasts) dysfunction. 
All of these processes interact and affect each other (Figure 1) (10, 13-15). 
 
Figure 1 – Main cornerstones in the pathogenesis of systemic sclerosis. Adapted from (Eckes B et al. 
2014.) and (Katsumoto TR et al. 2011) (13, 15). ECs – endothelial cells; ECM – extracellular matrix; ROS – 
reactive oxygen species. 
 
 
   Pathogenesis is dominated by early microvascular changes targeting endothelial 
cells (ECs), with the release of several mediators promoting an inflammatory response 
and vascular remodeling. As suggested by several lines of evidence, autoimmunity 
constitutes a key perpetuating event, with activation of both innate and adaptive 
immunity and with production of distinct autoantibodies. Autoantibodies to ECs, 
ischemia-reperfusion injury following Raynaud’s phenomenon (RP), generation of 
reactive oxygen species with inflammatory cell infiltration and subsequent cytokine 
production trigger myofibroblastic transformation of ECs and fibroblasts, inducing 
excessive production of collagens and other ECMs and ultimately leading to tissue 
fibrosis, under autocrine and paracrine control (9, 16). 
   A complex interplay between these major components establishes and maintains the 
inability of the vasculature to adequately react to the need for dilatation, constriction 
and growth of new vessels, causes increased deposition of ECM constituents and 
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facilitates immunological derangement (17). Various cell types involved in different 
pathophysiological events must be considered as part of an environment in which cell-
cell and cell-ECM interaction controls cellular activities (13). 
   The roles played by other ubiquitous molecular entities (such as lysophospholipids, 
endocannabinoids and their receptors and vitamin D) are just beginning to be 
understood and studied and may provide insights into new therapeutic approaches in 
SSc (14). 
 
1.2.1 Genetics and Epigenetics 
  There is evidence for genetic factors influencing susceptibility and familial clustering, 
more recently from genetic linkage and genome-wide association studies; different 
human leukocyte antigen (HLA) alleles and genetic polymorphisms have been 
associated with the predisposition for developing SSc and to SSc-specific 
autoantibodies in different populations (5, 13, 18). The heterogeneous clinical 
presentation probably reflects the influence of different genetic or triggering factors 
(14). It may be that the clinical course of the disease is influenced by the expression 
of micro-ribonucleic acids (miRNAs), which are epigenetically altered by body 
environmental factors (12, 19). 
   SSc is not inherited in a Mendelian fashion, with a genetic heritability of only 0.008 
(20). However, a positive family history signiﬁcantly increases the relative risk by 15 to 
19-fold in siblings and by 13 to 15-fold in ﬁrst-degree relatives (12, 21). Some ethnic 
groups have higher prevalence of SSc compared to the general population. Native 
American tribe Choctaw display a more homogeneous clinical and immunological 
phenotype than general population, supporting the role of genetics in SSc (22). 
   A recent systematic review provides an update on genomic and genetic studies of 
SSc (18). There is evidence that chromosomal breakage is a main feature in members 
of SSc families. HLA and non-HLA studies showed that alleles in the HLA-DRB1, HLA-
DQB1, HLA-DQA1, HLA-DPB1 genes and variants in signal transducer and activator 
of transcription 4 (STAT4), interferon-regulatory factor 5 (IRF5) and CD247 are 
frequently associated with SSc. The known variants are mostly located in non-coding 
regions of the genes and do not predict regulatory functions. Thus, no causal variant 
was identified and the biological consequences of the variants remain uncertain. 
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Moreover, most of the genes shown are also associated with other autoimmune 
diseases, defining what is called "shared autoimmunity" (9). DRB1*1101 and 
DPB1*1301 alleles were associated with the presence of anti-topoisomerase I 
antibodies, while DRB1*0401-22 and DRB1*0801-11 were associated with 
anticentromere antibodies (23). The combination of STAT4 and IRF5 was associated 
with an increased risk of pulmonary ﬁbrosis (24). 
   Genome-wide association studies have identified the single-nucleotide 
polymorphisms (SNPs) rs35677470 in DNASE1L3, rs12528892 in TAP2, rs9494883, 
rs5029939 and rs7749323 in TNFAIP3 and rs7574865 in STAT4 as those showing the 
strongest association with SSc subgroups. Regarding non-HLA gene interaction 
networks, nuclear factor of kappa light polypeptide gene enhancer in B cells 1, colony 
stimulating factor 3 receptor, STAT4, interferon-gamma, prolactin and interleukins (eg. 
IL-10, IL-13, IL-6, IL-2, IL-1B, IL-2RA, IL-12RB2) appear to be the main pivots 
mediating inflammation (18). 
   A functional genomic approach has lately performed a comprehensive comparison 
of available gene expression data from five different therapeutic trials in SSc (25). 
Molecular phenotyping of SSc patients prior to treatment may increase the likelihood 
of meaningful clinical response. 
   Epigenetic mechanisms are thought to represent the crossroad between genetics 
and environmental factors (12). The nature of the specific stimuli that trigger epigenetic 
modifications among patients with SSc remains mainly uncharacterized, but may 
include external factors (e.g. diet, chemicals, exposure to silica, toxins and drugs) and 
internal factors (e.g. ageing, sex hormones, hypoxia and oxidation injury) (26). 
   Current evidence demonstrates alterations in DNA methylation, histone code 
modifications and changes in miRNAs expression levels in SSc cells, particularly in 
fibroblasts, microvascular endothelial cells (MVECs), B and T cells (12). Epigenetic 
variation appears to target landmark pathways involved in SSc pathogenesis, such as 
transforming growth factor-beta (TGF-β) and downstream signaling cascades (27). 
   Hypermethylation of the promoter region of friend leukaemia virus integration gene 
(FLI1) leads to repression of friend leukaemia integration 1 (Fli1), a transcription factor 
which inhibits collagen gene expression. Epigenetic repression of FLI1 may play a key 
role in collagen deposition and tissue fibrosis. TGF-β signaling pathway is further 
15 | Introduction 
 
activated by miRNAs through upregulation of profibrotic molecules, such as Smad3 
and Smad4, or by downregulation of antifibrotic molecules, such as Smad7, that 
contribute to increased collagen synthesis and ECM expansion. miRNAs also 
modulate collagen gene expression; for instance, underexpression of miR-196a, Let-
7a and miR-29 are examples of post-transcriptional modification of collagen genes 
(26). 
   DNA hypermethylation and repression of key genes in SSc MVECs is maintained by 
upregulation of DNA (cytosine-5-)-methyltransferase 1 expression in MVECs. 
Hypermethylation of the promoter region of bone morphogenic protein receptor II and 
nitric oxide synthetase 3, and consequently underexpression of these genes in 
MVECs, leads to a cascade of events characterized by ECs apoptosis, 
vasoconstriction, recruitment of inflammatory cells, oxidation injury and ultimately 
activation of fibroblasts (26). 
   Epigenetic modifications are potentially reversible. Inherited epigenetic modifications 
can vanish after a variable number of cell divisions and epigenetic risk factors could 
be counteracted by treatment with currently available epigenetic modifier molecules, 
such as histone deacetylase inhibitors, DNA methyltransferase inhibitors and synthetic 
miRNAs (27). 
 
1.2.2 Environment 
   Several environmental factors have been related to an increased SSc susceptibility, 
such as the exposition to chemical compounds (silica, chlorinated solvents, 
trichloroethylene, welding fumes for men, aromatic solvents and ketones for women 
and white spirit for both genders), infectious agents or pregnancy, although the 
involvement of these factors in SSc development needs further exploration (24, 28). 
   Occupational exposure to silica/solvents is correlated with more severe forms of SSc, 
characterized by diffuse cutaneous involvement, interstitial lung disease, digital ulcers, 
myocardial dysfunction and association with cancer (29). 
 
1.2.3 Vascular Dysfunction 
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   Microvascular dysfunction is believed to be the cornerstone of SSc pathogenesis and 
its mechanisms will be more extensively reviewed elsewhere (II.3). 
 
1.2.4 Immunologic Dysfunction 
   Although the pathogenic relationship between systemic autoimmunity and the clinical 
manifestations of SSc remains uncertain, SSc patients display abnormal immune 
activation, in both innate and adaptive systems (30). 
   Macrophages/monocytes are involved in the pathogenesis of SSc, especially during 
its early stage, but their precise role in the disease is still unclear. Monocytes are one 
of the ﬁrst type of immune cells inﬁltrating SSc skin lesions (31). The presence of both 
M1 phenotype (pro-inflammatory) and strong M2 phenotype (classic activation and 
profibrotic/anti-inflammatory) signatures observed in the skin, blood, and lungs of SSc 
patients is very clear (32). M2 phenotype is characterized by low secretion of 
interleukin (IL)-12 and IL-23 and elevated IL-10 and by an increased synthesis of 
cytokines such as IL-4, IL-10, IL-13 or IL-6, connective tissue growth factor (CTGF) 
and arginase-1, which can stimulate the synthesis of collagen. Circulating and tissue 
macrophages/monocytes, plasmacytoid dendritic cells and stromal cells express a 
type 1 interferon signature that reflects an activation involving toll-like receptors 
(TLRs). Among TLRs, TLR-4 recognizes constitutive molecules of ECM, such as 
hyaluronic acid, fibronectin fragments or heparan sulfate. In animal models of TLR4 
knock-out mice, exposure to bleomycin induced less dermal and pulmonary fibrosis 
than in wild mice (9, 14). Proteome-wide analysis showed that CXCL4 is the 
predominant protein secreted by plasmacytoid dendritic cells in SSc, especially in early 
disease, both in the circulation and in the skin, predicting the risk of SSc progression 
(16). 
   Observations over several decades strongly implicate the adaptive immune system 
in SSc pathogenesis (14). 
   B cell homeostasis is disturbed during SSc (33, 34). Quiescent B cells are activated 
by four main mechanisms: B cell receptor stimulation (by autoantigens such as 
topoisomerase I) and deregulation (by abnormal expression of regulating co-receptors, 
autoantibodies such as anti-C22 and genetic polymorphisms), survival signal 
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stimulation by B cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) 
(secreted by peripheral blood mononuclear cell and myoﬁbroblasts), TLR stimulation 
by endogenous ligands (nucleosomes released from apoptotic cells, ECM degradation 
products) and T helper (Th) 2 cell stimulation by Th2 cytokines and direct cell-to-cell 
contact (34). An increased CD19/CD22 ratio may facilitate the sustained activation of 
B cells (16). 
   Activated B cells are mostly contained in the memory subset and display an 
increased susceptibility to apoptosis, which is responsible for their decreased number. 
This chronic loss of B cells enhances bone marrow production of the naïve subset, 
accounting for their increased number in peripheral blood. Activated B cells participate 
in the inﬂammatory and ﬁbrotic events observed during SSc through increased 
production of pro-inﬂammatory and proﬁbrotic cytokines (that promote activation of T 
cells and ﬁbroblasts), decreased production of anti-inﬂammatory cytokines, secretion 
of pathogenic autoantibodies (targeting ﬁbroblasts, ECM proteins or ECs), and direct 
cell-to-cell contact (notably through T cell co-stimulatory molecules) (33, 34). IL-10-
producing regulatory B cells, which induce generation of regulatory T cells (Treg) and 
can ameliorate autoimmune diseases, were found to be reduced in SSc, favoring 
autoaggression of B cells in this disease (35). 
   Antinuclear antibodies (ANA) are found in the sera of the vast majority of SSc 
patients and their antigenic specificity significantly correlates with clinical 
characteristics (16). Autoantibodies such as anti-topoisomerase I, anti-RNA 
polymerase III, anti-U3 RNP, anticentromere, anti-Th/To and anti-U1 RNP antibodies 
are currently the most reliable biomarkers for diagnosis, classification and prediction 
of specific clinical features of SSc (16, 24). Many other functional autoantibodies 
targeting ECs, intercellular adhesion molecule 1, endothelin-1 (ET-1) type A receptor, 
angiotensin II type I receptor, platelet-derived growth factor (PDGF) receptor and 
fibrillin-1 are known to induce activation or apoptosis of ECs. This facilitates 
inflammatory cell infiltration, cytokine production and myofibroblastic transformation of 
fibroblasts and ECs (16, 36). 
   These functional autoantibodies in SSc, as opposed to the classic antibodies often 
used as biomarkers, may actually be responsible for many of the key symptoms and 
manifestations of the disease, highlighting the potential value of treatment with 
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intravenous immunoglobulin, rituximab and/or newer therapies targeting B-cells and/or 
plasma cells (30, 36). 
   CD4+T cell activation is a key factor in the pathogenesis of SSc, with a predominance 
of Th 2 cells (which are mainly profibrotic) over Th1 cells (largely responsible for the 
secretion of inflammatory cytokines and growth factors) (9, 37). Activated T cells can 
release various cytokines (namely IL-4 and IL-13), resulting in inﬂammation and B cells 
stimulation, microvascular damage and ﬁbrosis (16, 38). Th17 and Treg activities are 
a hallmark of SSc, as Th17-type cytokines can induce both inﬂammation and ﬁbrosis. 
More recently, several studies have reported new T cell subsets, including Th9 and 
Th22 cells, along with their respective cytokines, in the peripheral blood, serum and 
skin lesions of individuals with SSc. The role of T follicular helper cells in SSc is not yet 
known (38). 
   In SSc, T cell inﬁltration is more obvious in the edema stage than in the hardening 
stage. CD4+ T cell inﬁltration is signiﬁcantly increased in skin lesions and peripheral 
blood of patients with SSc, and most of the T cell clones in skin lesions can express 
the CD4 co-receptor. T cell proliferation and clonal expansion in response to unknown 
speciﬁc antigens may occur. Activated T cells can activate adjacent ﬁbroblasts via 
direct cell-cell contact or via paracrine cytokine and chemokine production. 
Furthermore, autoreactive T cells may interact with B cells to promote the production 
of characteristic autoantibodies (38). 
   There is a general agreement regarding the decreased functional capacity of 
circulating Tregs in SSc. Some patients, particularly those with active disease, may 
have increased numbers of circulating Tregs, which parallel the expansion of the total 
pool of activated CD4+ cells, represent the inhibitory response of the immune system 
to its inappropriate activation, or occur as a compensatory move for their decreased 
suppressive activity. A decreased pool of circulating Tregs can be seen in other SSc 
patients, with even lower Treg numbers seen in patients with long-standing disease. 
Similarly, skin resident Tregs are depleted in advanced SSc but are active and can 
have a role in earlier disease stages. In addition, conversion of circulatory Tregs to 
Th17 cells and skin-resident Tregs to Th2 cells, producing corresponding inflammatory 
and profibrotic cytokines, has been demonstrated in SSc (39). 
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   IL-17-producing Th17 cells are signiﬁcantly increased in the peripheral blood, skin 
lesions and lung tissues of patients with SSc. Serum-derived IL-17A from SSc patients 
can promote proliferation, migration, collagen synthesis and secretion of SSc patient-
derived dermal vascular smooth muscle cells (vSMCs), further aggravating 
vasculopathy in SSc. A positive feedback loop may exist in SSc whereby IL-17 can 
either directly or indirectly promote the activation of ﬁbroblasts, ECs and vSMCs, and 
in turn the cytokines secreted by these cells can enhance Th17 cell differentiation (38). 
 
1.2.5 Extracellular Matrix Dysfunction and Fibrosis 
   The end of the pathogenic sequence of SSc is fibrosis (9). Fibrogenesis is a 
consequence of a multistage process, initiated by deregulated tissue repair responses, 
in which aberrantly sustained production of cytokines, growth factors and angiogenic 
factors tilt tissue homeostasis towards interstitial hyperplasia and excessive 
accumulation of ECM (37).  
   Fibrosis in SSc is typically characterized by prolonged and/or exaggerated activation 
of fibroblasts, a key feature of which is the differentiation of fibroblasts, vSMCs or ECs 
into myofibroblasts (9, 24, 37). Endothelial-to-mesenchymal transition (EndoMT) 
consists on a nonmalignant phenomenon of cellular trans-differentiation, by which ECs 
undergo a phenotypical conversion, loosing vascular EC markers and acquiring 
myoﬁbroblast-like features (40). EndoMT, which is enhanced by the synergistic action 
of endohelin-1 and TGF-β, appears to be a critical event linking endothelial dysfunction 
and the development of dermal ﬁbrosis in SSc (40-42). ET-1 antagonists seem able to 
antagonize this phenomenon in vitro (41). 
   Activated myofibroblasts, which are resistant to apoptosis, synthesize and deposit 
ECM components, leading to ECM accumulation, increased collagen crosslinking, 
contraction and fibrosis. Fibrotic tissues exhibit increased tissue pressure and hypoxia, 
further activating resident fibroblasts and escalating fibrotic mechanisms (9, 37). 
   Cells of the innate and adaptive immune system elaborate a variety of cytokines and 
chemokines in addition to TGF-β and IL-4 (such as IL-6, PDGF, IL-1, IL-13, IL-17, IL-
5, monocyte chemoattractant protein-1 and CTGF) that have been found to be 
increased in serum or in tissues in which excessive ECM is accumulating in SSc. 
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These cytokines/chemokines are at the interface between the immune system and 
fibroblasts (14). The close interaction between the immune system and ﬁbrosis gives 
opportunities for intervention (31). 
   In SSc, representative profibrotic growth factors and cytokines encompass TGF-β, 
CTGF, PDGF, IL-6 and IL-4/IL-13 and play a pivotal role in collagen production from 
myofibroblasts (16). 
  TGF-β is considered the central regulatory factor of fibrosis in SSc (9). It binds the 
TGF-β receptors and downstream signaling occurs through the canonical Smad 
pathway, inducing gene transcription of type I collagen, α smooth muscle actin (αSMA) 
and CTGF. TGF-β causes increased collagen and ECM in dermal ﬁbroblasts and 
induces epithelial to mesenchymal transition, being clearly perturbed in SSc (31). The 
expression of αSMA is a hallmark of myofibroblastic transformation of activated 
fibroblasts, which is also frequently detected in SSc (16). 
   The expression of CTGF is induced by TGF-β, ET-1 and hypoxia. The levels of CTGF 
are markedly elevated in the lesional skin of SSc patients and in SSc mouse models 
(16). 
   The expression of PDGF and its receptors is elevated in SSc fibroblasts and in the 
lesional skin. Agonistic antibodies to the PDGF receptor were found in SSc patients 
and appear to induce a myoﬁbroblast phenotype in dermal ﬁbroblasts, although further 
research is required (16, 31). 
  In SSc, activated B cells secrete IL-6, which directly stimulates fibroblasts and 
induces type 1 collagen expression via enhancing TGF-β-Smad3 signaling pathway. 
Both IL-4 and IL-13 likely activate fibroblasts and induce type 1 collagen synthesis via 
a TGF-β-independent approach, and serum levels of IL-4 and IL-13 were significantly 
higher in patients with SSc compared to healthy controls (16). 
   Platelets may be actively involved in the pathogenesis of SSc by activating immune 
responses and facilitating fibrosis (43). Platelets can be activated by the damaged ECs 
and subsequently release bioactive molecules stored in their granules, such as TGF-
β and serotonin. Serotonin may bind to and activate 5HT2B receptors on nearby 
ﬁbroblasts, leading to enhanced collagen production. TGF-β released from activated 
platelets at sites of endothelial damage may be involved in EndoMT. Furthermore, 
activated platelets express CD40L on their surface and may interact with B cells by 
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providing co-stimulatory signals. Theoretically, this may facilitate a breach in 
immunologic tolerance and auto-antibody production (43). 
   The transcription factor Fli1 is a negative regulator of ﬁbrosis, and its expression has 
been shown to be substantially reduced in SSc ﬁbroblasts and SSc skin, whereas 
overexpression of Fli1 results in decreased collagen synthesis. Interestingly, the 
tyrosine kinase inhibitor imatinib has been shown to alter the DNA-binding ability and 
protein stability of Fli1 thereby reducing collagen levels (31). In a recent study, gene 
silencing of Fli1 induced a SSc-like molecular phenotype in keratinocytes (44). Keratin 
14-expressing epithelial cell-specific Fli1 knockout mice spontaneously developed 
dermal and esophageal fibrosis with epithelial activation. Furthermore, they developed 
remarkable autoimmunity with interstitial lung disease derived from thymic defects with 
downregulation of autoimmune regulator (Aire). Fli1 directly regulated Aire expression 
in epithelial cells. Epithelial Fli1 deficiency might be involved in systemic autoimmunity 
and selective organ fibrosis in SSc. 
 
   In Figure 2, a schematic representation of the main mechanisms involved in SSc 
pathogenesis is provided. 
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Figure 2 – Synthesis of systemic sclerosis pathogenesis. Adapted from (Allanore Y. 2016.) (9). 5HT – 
serotonin; CMH – major histocompatibility complex; CTGF – connective tissue growth factor; ET-1 – endothelin-1; 
Endo-MT – endothelial-to-mesenchymal transition; IFN-α – alpha interferon; IL – interleukin; NO – nitric monoxide; 
PDGF – platelet-derived growth factor; PF4 – platelet factor 4; ROS – reactive oxygen species; TGF-β – 
transforming growth factor-beta; TLR – toll-like receptor; VEGF – vascular endothelial growth factor. 
 
 
 
 
1.3 Classification Criteria 
 
   New American College of Rheumatology/European League Against Rheumatism 
(ACR/EULAR) classification criteria were published in 2013 (Table 1) (45). 
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Table 1 – The American College of Rheumatology/European League Against Rheumatism criteria for 
the classification of systemic sclerosis. Adapted from (van den Hoogen et al. 2013.) (45).* 
Item Sub-item(s) 
Weight/
score† 
Skin thickening of the fingers of both hands extending 
proximal to the MCP joints (sufficient criterion) 
- 9 
Skin thickening of the fingers (only count the higher 
score) 
Puffy fingers                        2 
Sclerodactyly of the fingers 
(distal to MCP joints but 
proximal to the PIP joints) 
4 
Fingertip lesions (only count the higher score)                                         Digital tip ulcers                                                                                        2 
Fingertip pitting scars 3 
Telangiectasia - 2 
Abnormal nailfold capillaries - 2 
Pulmonary arterial hypertension and/or ILD (maximum 
score is 2) 
Pulmonary arterial hypertension 2 
ILD 2 
Raynaud’s phenomenon - 3 
SSc-related autoantibodies (anticentromere, anti-
topoisomerase I [anti-Scl-70], anti-RNA polymerase 
III) (maximum score is 3) 
Anticentromere 3 
Anti-topoisomerase I  
Anti-RNA polymerase III  
*These criteria are applicable to any patient considered for inclusion in a systemic sclerosis study. The criteria 
are not applicable to patients with skin thickening sparing the fingers or to patients who have a scleroderma-like 
disorder that better explains their manifestations (eg, nephrogenic sclerosing fibrosis, generalized morphea, 
eosinophilic fasciitis, scleredema diabeticorum, scleromyxedema, erythromyalgia, porphyria, lichen sclerosis, 
graft-versus-host disease, diabetic cheiroarthropathy). 
†The total score is determined by adding the maximum weight (score) in each category. Patients with a total 
score of ≥9 are classified as having definite systemic sclerosis. 
ACA – anticentromere antibodies; ILD – interstitial lung disease; MCP – metacarpophalangeal; PIP – proximal 
interphalangeal; SSc – systemic sclerosis. 
 
   In a cohort of patients with mild/early SSc, the new ACR/EULAR classification criteria 
showed higher sensitivity (79.6%) and classified more patients as definite SSc patients 
than the previous ACR criteria (53.3%) (46). This current classification system is also 
characterized by a high specificity but still cannot identify patients in the very early 
phases of the disease process (47). 
   The two subset criteria first proposed by LeRoy in 1988 and modified in 2001 (Table 
2) have been the most influential for the sub-classification of SSc (48). 
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Table 2 – Criteria of classification of limited and diffuse cutaneous SSc according to LeRoy et al. (49). 
Limited cutaneous SSc Diffuse cutaneous SSc 
• RP for years (occasionally decades) 
• Skin involvement limited to hands, face, feet, 
and forearms (acral) or absent 
• Late incidence of pulmonary hypertension, 
with or without ILD, trigeminal neuralgia, skin 
calcifications and telangiectasia 
• ACA (70–80%) 
• Dilated nailfold capillary loops, usually without 
capillary dropout 
• Onset of RP within 1 year of onset skin 
changes (puffy or hidebound) 
• Truncal and acral skin involvement, tendon 
friction rubs 
• Early and significant incidence of ILD, oliguric 
renal failure, diffuse gastrointestinal disease 
and myocardial involvement 
• Absence of ACA 
• Nailfold capillary dilatation and capillary 
destruction 
• Anti-topoisomerase I antibodies (30%) 
ACA – anticentromere antibodies; ILD – interstitial lung disease; RP – Raynaud’s phenomenon; SSc – systemic 
sclerosis. 
 
   Systemic sclerosis sine scleroderma is an uncommon form of the disease (2%), 
without clinically detectable skin involvement, yet with visceral and immunological 
manifestations that are characteristic of SSc (50, 51). 
 
1.4 Clinical Presentation and Diagnosis 
 
   The diagnosis of SSc is made clinically and generally suggested by the presence of 
typical skin thickening and hardening (sclerosis), which usually begins in the fingers. 
RP usually precedes skin sclerosis by several weeks to several years. The diagnosis 
is supported by the presence of additional extra-cutaneous features (Table 3), nailfold 
videocapillaroscopy (NVC) SSc patterns and characteristic autoantibodies (49). 
   Data from the EUSTAR database (7655 patients from 174 centers) showed that the 
most prominent clinical hallmarks of SSc were RP (96.3%), ANA (93.4%) and typical 
capillaroscopic patterns (90.9%). Scleroderma was more common on fingers and 
hands than on any other part of the skin (52). 
   The presence of characteristic autoantibodies is supportive of the diagnosis of SSc. 
Specific autoantibodies include anticentromere (ACA) (15-43%), anti-topoisomerase I 
(anti-Scl-70) (21-34%) and anti-RNA polymerase III (5%). Other autoantibodies are 
more rarely found in SSc patients, including anti-Th/To, anti-U3 RNP, anti-PM/Scl and 
anti-U1 RNP (24, 49). Autoantibodies in SSc are highly heterogeneous, reflecting the 
multiplicity of the disease. An autoantibody profile is a useful aid in refining disease 
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subsets (10). Moreover, autantibodies are important prognostic indicators and valuable 
for predicting skin, vascular and internal organ involvement (13, 49, 53). ACA are 
associated with limited cutaneous systemic sclerosis (lcSSc), pulmonary arterial 
hypertension (PAH), longer time to onset of visceral complications and lower mortality 
rates, while anti-topoisomerase I antibodies are associated with diffuse cutaneous 
systemic sclerosis (dcSSc), increased lung involvement and higher mortality rates (53). 
The presence of anti-RNA polymerase III is associated with dcSSc, scleroderma renal 
crisis and tendon contractures (24). Classification of the disease by identifying the 
dominant SSc specific autoantibody, in addition to skin and organ involvement, has 
been proposed (54, 55). 
 
Table 3 – Main clinical manifestations of SSc (2, 5, 6, 24, 52, 56-58). 
Involvement Clinical Presentation Prevalence (%) Main Diagnosis Tests 
LcSSc DcSSc 
Vascular 
Raynaud’s phenomenon 97 96 NVC 
Digital ulcers 33 42  
Cutaneous 
 
Sclerosis 
Telangiectasia 
Calcinosis 
98 
75 
25 
Modified Rodnan Skin Score 
 
Pulmonary 
Interstitial lung disease 31 52 Chest X-ray, chest HR-CT, 
pulmonary function tests with 
DLCO, 6-minute walking 
test, TTE, RHC 
Pulmonary arterial 
hypertension 
21 22 
Renal Scleroderma renal crisis 1 4 
Blood pressure, renal 
ultrasound, GFR, urine 
protein/creatinine ratio 
Cardiac 
Pericardial disease 
Conduction block 
Diastolic dysfunction 
6 
10 
17 
12 
12 
18 
ECG, TTE with Doppler, 
Holter-ECG, coronary 
angiography, cardiac MRI 
Digestive 
Esophageal 
Gastric 
Intestinal 
66 
22 
23 
70 
27 
24 
EGD, 
esophageal manometry, 
colonoscopy 
Musculo- 
skeletal 
Myositis 
Arthritis 
Tendon friction rubs 
Weakness 
5 
13 
5 
19 
13 
20 
18 
24 
Joint X-ray/MRI, muscle 
enzymes, electrodiagnostic 
testing, muscle biopsy 
DcSSc – diffuse cutaneous systemic sclerosis; DLCO – diffusing lung capacity for carbon monoxide; ECG – 
electrocardiography; EGD – esophagogastroduodenoscopy; GFR – glomerular filtration rate; HR-CT – high 
resolution computed tomography; LcSSc – limited cutaneous systemic sclerosis; MRI – magnetic resonance 
imaging; NVC – nailfold videocapillaroscopy; RHC – right heart catheterization; TTE – transthoracic 
echocardiography. 
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     Some patients with SSc have signs of other defined connective tissue diseases, 
such as systemic lupus erythematosus, rheumatoid arthritis or polymyositis. This is 
called overlap syndrome and occurs in roughly 10% of SSc patients (8). SSc has an 
increased association with certain malignancies and, like other autoimmune 
diseases, it can present as a paraneoplastic syndrome, the latter being associated with 
a more severe/refractory disease course (5). 
 
 
1.5 Management 
 
   The multifaceted nature of SSc, with variable extension of skin and internal organ 
involvement, creates significant challenges for the management of this disorder. 
Moreover, there is a lack of good quality randomized studies on most of the organ-
based manifestations of the disease (10). A comprehensive guideline of the British 
Society for Rheumatology and British Health Professionals in Rheumatology has been 
published in 2016 (59). 
   Because SSc is a heterogeneous disease with an unpredictable course, treatment 
must be tailored to the single patient. Effective management depends on secure 
diagnosis and subset classification (based upon the extent of skin thickening), stage 
of disease, extent of organ-based complications and presence of overlap features. All 
potential problems should be addressed with early identification and appropriate 
therapy (6, 59). 
   Both limited and diffuse cases should be treated for vascular manifestations. Active 
early diffuse cutaneous SSc requires immunosuppression. In all cases of SSc, vigilant 
follow-up to determine significant organ-based complications is mandatory (59).  
   Treatment options for SSc are still limited to specific aspects of organ involvement, 
especially for scleroderma renal crisis, interstitial lung disease and PAH (6, 48, 59).  
Therapies targeting the vasculature (namely ET-1 receptor antagonists, 
phosphodiesterase-5 inhibitors, angiotensin-converting enzyme inhibitors, 
prostacyclins), the immune system and/or the fibrotic process (methotrexate, 
cyclosporine, cyclophosphamide, azathioprine, mycophenolate mofetil, rituximab, 
tocilizumab, abatacept) have been or are being evaluated in SSc. Autologous 
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haematopoietic stem cell transplantation and intravenous immunoglobulins are 
reserved to unresponsive SSc patients (19). Current established therapeutic 
approaches focus mainly on vascular or inflammatory components; however, at least 
one putatively antifibrotic substance, nintedanib, is being tested for SSc interstitial lung 
disease (60). 
  Besides pharmacological treatments, the eviction of aggravating factors (smoking, 
vasoconstrictive drugs, cold) remains a major issue (24). Patients should be educated 
to risk factors and prognosis and allowed to actively participate in treatment; this should 
follow a holistic approach, recognizing the impact of the disease on lifestyle and 
relationships (3, 6). 
   Despite many advances and an increasing number of clinical trials in SSc, no 
treatment has been shown to modify mortality on controlled clinical trials. No drug has 
been so far labelled to reduce skin ﬁbrosis or organ involvements. The interactions 
between vasculopathy, immune disturbances and ﬁbroblast activation are complex and 
may hamper the recognition of a single effective therapeutic agent. A better 
comprehension of disease pathogenesis may lead to the development of targeted 
approaches, in order to attenuate key mediators of signaling pathways (6, 61). 
   Targeted therapies (antiﬁbrotic agents, anti-CD20 antibodies, etc.) are currently 
being investigated (24). Refocusing immunotherapies already used in other diseases 
makes sense and is in line with genetic data that demonstrated the shared 
autoimmunity between autoimmune disorders (61). Two novel approaches – the IL-6 
receptor blocker tocilizumab and nintedanib – are being evaluated in phase III clinical 
trials. 
   Ideal disease-modifying therapy should address the inflammatory, vascular, and 
fibrotic aspects of SSc (1). Combining immune and antiﬁbrotic therapies might be a 
very efﬁcient treatment for the disease (61). 
  
 
1.6 Prognosis 
 
  In a meta-analysis, the pooled standardized mortality ratio for SSc was measured as 
3.53 (95% CI 3.03 to 4.11), without signiﬁcant changes over time (62). Nevertheless, 
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improved survival rates for SSc have been reported in recent studies (24, 63). In an 
Italian study, the 10-year survival showed a clear-cut increase from 69% to 81%, in the 
same center (63). Possible explanations include improved therapeutic management, 
changes in the natural history of the disease, earlier referral of the patients and, even 
more likely, a better recognition of patients with milder disease (61). 
   SSc requires multicenter collaboration to reveal comprehensive details of disease-
related causes of morbidity and mortality (52). Among 987 patients with SSc, recruited 
from the nationwide Spanish Scleroderma Registry (RESCLE) between 1990 and 
2009, SSc-related factors were responsible for 72% of all deaths in patients diagnosed 
within 1990-99, compared to 48% within 2000-09. Pulmonary involvement was the 
leading cause of death in both decades, while renal causes decreased since 1990 and 
cardiac causes tripled their ratio (64). 
   Independent risk factors for mortality have been identified, namely elevated age at 
RP onset, increased modiﬁed Rodnan skin score, positive anti-topoisomerase I 
antibodies, proteinuria, PAH on echocardiography, pulmonary restriction, dyspnea, 
decreased diffusing lung capacity for carbon monoxide and extent of lung disease on 
chest high resolution computed tomography scan (24, 65). 
   A single clinical manifestation, even the extent of cutaneous sclerosis, is not per se 
a sufﬁcient prognostic indicator in each patient. The thorough clinical assessment and 
the early detection of organ damage are decisive for a correct prognostic evaluation 
and effective therapeutic interventions (63). 
 
 
2. Very Early Diagnosis of Systemic Sclerosis 
 
   Early diagnosis of SSc may allow an earlier treatment and a slower disease 
progression, being of pivotal importance (66). 
   RP is the clinical reflection of diffuse microvascular damage in SSc and often 
precedes skin and visceral involvement by years or decades (67). In 1996, the term 
“pre-scleroderma” intended to identify patients with RP plus digital ischemic changes 
and typical NVC changes or disease-specific circulating ANA (68). In 2001, LeRoy and 
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Medsger proposed that patients with RP who had both a SSc pattern on NVC and SSc-
specific autoantibodies be classified as having “early-SSc” (69). Seven-years later, a 
prospective study by Koenig et al. has validated these criteria: patients with RP in 
whom both predictors were present at baseline were 60 times more likely to develop 
definite SSc than were patients without these predictors, with a sensitivity of 47%; 
when the presence of an abnormal NVC and/or SSc autoantibodies at baseline was 
considered, the sensitivity increased to 89% (67). This study has also shown that the 
incidence of progression from isolated RP to definite SSc was 12.6 % and that patients 
classified as early-SSc would ultimately develop definite SSc. 
   EUSTAR proposed a set of preliminary criteria for the very early diagnosis of 
systemic sclerosis (VEDOSS) that are currently under validation (70). The presence of 
positive ANA, RP and puffy swollen fingers turning into sclerodactyly constitute a “red 
flag” to suspect of SSc; if these patients additionally have positive SSc-specific ANA 
(ACA, anti-topoisomerase I, anti-RNA polymerase III) and/or NVC with SSc pattern, 
EUSTAR criteria for VEDOSS are fulfilled (Figure 3). In a preliminary analysis of 
VEDOSS EUSTAR multicenter study, almost 90% of patients with “red flags” had ACA 
or anti-topoisomerase I antibodies and/or a NVC SSc pattern (71). 
 
Figure 3 – Progression of systemic sclerosis. Adapted from (Matucci-Cerinic M et al. 2012.) (72). 
    
   VEDOSS Programme has been designed to anticipate the diagnosis of SSc and to 
examine whether this may change the disease prognosis (66, 72, 73). In order to 
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achieve very early/early diagnosis of SSc, patients with RP who present to a 
specialized center should be evaluated both for NVC abnormalities and for SSc-
specific autoantibodies, including anti-Th/To and anti–RNA polymerase III (67).  
   In early SSc, marker autoantibodies and NVC patterns may be related to different 
clinical-preclinical features and circulating activation markers at presentation (74). 
Indeed, a label of “Undifferentiated Connective Tissue Disease at risk for SSc”, with 
three different subsets (i.e. RP associated to marker autoantibodies and SSc NVC 
abnormalities; RP associated to marker autoantibodies in the absence of SSc NVC 
abnormalities; and RP associated to SSc NVC abnormalities without any detectable 
marker autoantibody) has been proposed (75). 
   Early clinical symptoms (i.e. RP) and biomarkers (i.e. serum autoantibodies) appear 
to represent the best “early signals” of possible SSc to be considered (19). In a 
retrospective study of 497 patients with primary RP, SSc NVC pattern and anti-
topoisomerase I antibodies were independent risk factors for SSc. The presence of 
both SSc NVC pattern and anti-topoisomerase I or SSc NVC and ACA was also a good 
predictor for the development of SSc (76). It is crucial to focus on these signs to look 
for valid predictors of disease evolution and to conduct a close follow-up of the patients, 
in order to capture the slightest change in clinical condition, as soon as possible (47).  
   A subclinical scleroderma-related internal organ involvement (heart, lung, 
esophagus) was detected in patients with early-SSc (without clinical manifestations 
other than RP but with SSc marker autoantibodies and/or typical NVC abnormalities) 
(68). There is also evidence for esophageal and anorectal involvement in VEDOSS 
and a history of digital ulcers significantly correlated with gastrointestinal involvement 
in these patients (77, 78). This corroborates the impending need to screen for visceral 
involvement in VEDOSS patients, so it can be early managed, efficiently controlling 
disease progression (73). 
   In the EUSTAR cohort, 695 SSc patients with a baseline visit within one year after 
RP onset were evaluated for incident non-RP manifestations (79). The most frequent 
were skin sclerosis (75%), gastrointestinal symptoms (71%) and diffusing lung capacity 
for carbon monoxide <80% of predicted (65%); of note, cardiac involvement was 
already present in 32%, mainly diastolic dysfunction. Approximately half of all incident 
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organ manifestations occurred within two years and had a simultaneous rather than a 
sequential onset. 
   The time gap between the appearance of early signs and the development of internal 
organ fibrosis, should be considered as the “window of opportunity” for SSc patients 
(72, 73). The choice of an aggressive treatment before the patient fulfills SSc validated 
criteria may expose some patients to overtreatment and risks connected to side effects 
(72). This might be overtaken when criteria for VEDOSS and predictors of severity in 
this cohort are validated. One should consider randomized controlled trials to evaluate 
mild immunosuppression in RP patients with typical SSc NVC changes and anti-
topoisomerase I and/or anti-RNA III polymerase autoantibodies, in a well-monitored 
environment (80). 
   The identification of genetic, clinical and circulating markers are crucial steps to lift 
the curtain on the prognosis of a very early-SSc patient without skin sclerosis, 
burdened by the risk of developing severe organ involvement (73). 
   The negative predictive value of testing in the very early phase might identify SSc 
patients who will not progress to major complications, thus sparing them from an 
aggressive overtreatment (72). On the other hand, positive predictive valued tests 
would allow high-risk patients to be identified and straightly monitored, to initiate 
appropriate treatment as soon as SSc manifestations appear. Studies on preventive 
therapies could also be a reality (73). 
   The EUSTAR effort to validate the criteria of the VEDOSS project will definitively 
shed a new light in SSc approach (47). Rather than waiting for the clinical overt disease 
to set in, eyes are geared to diagnose the disease “early” or “very early”, so that, in the 
future, selected SSc can be treated before clinical complications occur (19). 
 
 
3. Microvasculopathy of Systemic Sclerosis 
 
   Microvascular lesions are a main feature of SSc and may play a central pathogenic 
role. Vasculopathy accompanies the pathogenesis of SSc from the early beginning and 
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is responsible for the most significant clinical determinants of morbidity and mortality, 
including PAH, digital ulcers and scleroderma renal crisis. 
   The etiology of the initial vascular damage in SSc is not known. Viral agents 
(especially human cytomegalovirus) and other environmental factors, cytotoxic T cells, 
antibody-dependent cellular cytotoxicity, anti-endothelial cell antibodies and ischemia-
reperfusion injury are all suggested mechanisms for ECs damage (14). 
   Initial vascular injury generates structural changes (destructive and proliferative 
obliterative vasculopathy caused by impaired compensatory vasculogenesis and 
angiogenesis) and functional abnormalities of the vasculature (altered expression of 
cell adhesion molecules, ECs dysfunction, activation of endothelial-to-mesenchymal 
transition, impaired coagulation/ fibrinolysis system), eventually leading to constitutive 
activation of fibroblasts in various organs (Figure 4) (81). ECs injury is proposed as 
the crucial initiating event leading to vascular remodeling, with intimal proliferation of 
arterioles, capillary breakdown and blood vessel occlusion. ECs dysfunction is present 
and prominent in distinct aspects of cell survival, angiogenesis and vasculogenesis, 
and disturbed interactions between ECs and various other cells contribute to SSc 
vasculopathy (42). 
   The participation of functional autoantibodies in endothelial apoptosis/activation of 
SSc deepens the understanding about the pathophysiologic mechanisms underlying 
autoimmune vasculopathies (36, 82). Anti-endothelial cell antibodies cause endothelial 
cell apoptosis (83). Anti-ICAM1 antibodies induce the production of reactive oxygen 
species and expression of VCAM-1, which may facilitate the attachment of immune 
cells (84). Antibodies against angiotensin II type I receptor (anti-AT1R) and ET-1 type 
A receptor (anti-ETAR) are detected in most SSc patients (16). These agonistic 
antibodies upregulate ECs expression of TGF-β, IL-8 and VCAM-1 and cause fibrosis, 
vasoconstriction and recruitment of immune cells. The expressions of anti-ETAR and 
anti-AT1R are found to be highest in patients with early SSc (85, 86). 
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Figure 4 – The potential mechanism of SSc vasculopathy leading to tissue fibrosis. Adapted from 
(Asano Y, Sato S. 2015)  (81). CTGF – connective tissue growth factor; DUs – digital ulcers; ECs – endothelial 
cells; GlyCAM-1 – glycosylation dependent cell adhesion molecule-1; ICAM-1 – intercellular cell adhesion molecule-
1; PAH – pulmonary arterial hypertension; PDGF – platelet-derived growth factor; SRC – scleroderma renal crisis; 
TGF-β – transforming growth factor-β; vSMCs – vascular smooth muscle cells; vWF – von Willebrand factor. 
 
    
   The activation of ECs leads to the expression of adhesion molecules, intercellular 
adhesion molecule-1 (ICAM) and VCAM-1, which promote the recruitment of 
inflammatory cells (87).  
   Capillary damage of SSc is characterized by endothelial apoptosis, intimal and 
medial fibrous thickening and adventitial fibrosis, with perivascular infiltration of 
macrophages, B cells and T cells. Precapillary arterioles then show endothelial 
proliferation and mononuclear inflammatory infiltrates, followed by intimal proliferation 
and luminal narrowing (16). The evolution of the lesions leads to capillary rarefaction 
and to obliteration of the small vessels, which is responsible for hypoxia and oxidative 
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stress (9). Pericytes also proliferate and contribute to increased vascular wall thickness 
(14). 
   Both activated ECs and recruited inflammatory cells constitute an important source 
of pro-inflammatory cytokines and profibrotic molecules, which stimulate the 
proliferation of vSMCs and the synthesis of ECM components (9, 81). ECs exhibit 
substantial plasticity and can undergo endothelial-to-mesenchymal transition, 
acquiring ECM-producing myoﬁbroblast features (40). 
   Damaged ECs release several molecular substances into the circulation that 
interfere with coagulation homeostasis (42). Sub-endothelial tissue forms a nidus for 
platelets to aggregate and initiates fibrin deposition and intravascular thrombus 
formation (14). 
   Impaired vascular permeability and tone are the earliest symptoms of vascular 
pathology in SSc (88). Increased ET-1 levels and a defective production of 
prostacyclins and nitric oxide enhance vasoconstriction, inﬂammation and vascular 
remodeling and disturb the physiological antithrombotic action of the endothelium (9, 
24). The interaction between ECs and platelets also plays an important role in vascular 
tone regulation in SSc (42). 
   The absence of compensatory angiogenesis in SSc will be explored in the next 
sections, as well as the significant role of vascular endothelial growth factor (VEGF), 
whose synthesis is stimulated by increased endothelial permeability and hypoxia 
phenomena (II.3.2 and II.3.3). 
   The role of circulating endothelial progenitor cells (EPCs) in SSc vasculopathy is 
unclear (81). Contradicting studies have reported their decrease or increase in the 
circulation of SSc patients (88). EPCs may be inadequately recruited and therefore 
may not contribute to vascular repair or there may be an early apoptosis of these cells 
(14). 
   Microangiopathy appears to be the best evaluable predictor of SSc development and 
may precede symptoms of internal organ involvement by many years. Therefore, the 
activity and severity of digital vascular disease in patients presenting with RP – often 
the earliest clinical sign of vascular involvement in SSc – must be measured and 
monitored (2). A recent study evaluated post-occlusive reactive hyperemia (PORH) by 
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laser speckle contrast analysis; a statistically significant difference was detected in the 
PORH peak flow between VEDOSS and established SSc and PORH peak flow 
decreased according to the capillaroscopic pattern from “early” to “late” (89). POHR 
might prove a tool to separate pre-clinical from full-blown SSc. 
 
3.1 Biomarkers of microvasculopathy in Systemic Sclerosis 
 
     A biological marker (biomarker) was defined as “a characteristic marker that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention” (90). 
A biomarker should be easily obtainable, preferably by noninvasive means and 
eventually be validated in clinical studies (4).  
   There is an unmet need for validated biomarkers in SSc (4, 91). The discovery and 
validation of biomarkers can help on identifying disease risk, improving early diagnosis 
and prognosis, better designing clinical trials and assessing response to treatment, as 
well as on further elucidating the underlying pathogenic mechanisms of this disease 
(92). 
   Biomarkers for SSc can be categorized into activity biomarkers, severity biomarkers, 
predictive biomarkers and biomarkers for specific clinical features (skin fibrosis, lung 
fibrosis, PAH, peripheral vasculopathy, gastrointestinal involvement and malignancy) 
(91). 
  The first and best developed biomarkers in SSc are assessments of disease status 
or severity at a point in time (93). At present, SSc-speciﬁc autoantibodies are the most 
useful biomarkers for diagnosis and predicting clinical features (91). Otherwise, 
biomarkers speciﬁc only for SSc have not yet been identiﬁed (94). A recent review by 
Matsushita T. et al highlighted the biomarkers most strongly associated to SSc, which 
include anti-RNA polymerase III as a predictive biomarker of malignancy and gastric 
antral vascular ectasia, CXCL4 as a predictive biomarker of worsening skin sclerosis 
and lung fibrosis, the DETECT algorithm as a predictive biomarker for PAH, CCL2 as 
an activity biomarker of the skin and lungs and interferon-inducible chemokine score 
as a severity biomarker (91). 
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   Current research is focusing on the discovery of useful mechanistic biomarkers, 
reflecting ongoing inflammatory or fibrotic activity in the skin and internal organs, as 
well as being predictive of future disease course (92, 95, 96). Aggregate indices of 
multiple biomarkers are being applied for improving prognostic discrimination, and 
similarly genomic expression patterns and disease trajectory analysis have 
demonstrated early promise in grouping patients with shared clinical characteristics 
(97). Biomarkers predicting future disease course are particularly important, so that 
patients with spontaneously regressive disease are not entered into clinical trials and 
are not treated aggressively with disease-modifying medications (91, 93). 
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3.1.1 First Paper 
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   Several other promising biomarkers related to the evaluation and management of 
SSc patients have more recently been presented (91, 92). 
   A systematic review from Mostmans Y. et al identified reliable biomarkers of ECs 
dysfunction in SSc vasculopathy (42). The most representing biomarkers described 
were adhesion molecules for ECs activation; anti-endothelial cell antibodies for ECs 
apoptosis; VEGF, its receptor VEGFR-2 and endostatin for disturbed angiogenesis; 
endothelial progenitor cells for defective vasculogenesis; ET-1 for disturbed vascular 
tone control; von Willebrand Factor (vWF) for coagulopathy; and IL-33 for disturbed 
communication between ECs and the immune system (occurring early in SSc). 
Emerging biomarkers included VEGF165b, IL-17A and the adipocytokines (namely 
resistin and chemerin). The role of endothelial-to-mesenchymal transition in the 
pathogenesis of SSc vasculopathy still needs clariﬁcation. 
   Other studies have corroborated that endoglin and VEGF serum levels are potential 
risk factors for the occurrence of new digital ulcers (DUs), with VEGF showing a 
predictive value (98), and that ET-1 is a strong predictor of new DUs in SSc patients 
(99, 100). Asymmetric dimethylarginine has also been implicated as an independent 
predictor of new DUs (100).  
   Endostatin was significantly increased in all NVC stages, while angiostatin was only 
elevated in “active” and “late” phases (101). Besides peripheral vasculopathy, 
endostatin was also found to represent a marker of renal scleroderma-associated 
vasculopathy (102). A negative correlation was observed between serum levels of 
endostatin and estimated glomerular filtration rate. Moreover, in SSc patients with high 
resistive index in renal Doppler ultrasound, serum levels of endostatin were 
signiﬁcantly higher than in patients with normal resistive index. 
   The role of angiopoietin(Ang)/Tie2 system in SSc was lately readdressed (103). SSc 
dermal microvessels abundantly expressed Ang-2, but not Ang-1, compared to healthy 
controls. Membrane bound Tie2, which ensures vessel stability, was profoundly 
decreased in SSc microvessels, while the levels of soluble Tie 2, which attenuates 
Tie2 signaling, were increased already in early disease. Both in skin and sera of SSc 
patients, the Ang1/2 ratio was reduced, being lowest in patients with DUs. 
   Decreased serum levels of the pro-angiogenic epidermal growth factor-like domain 
7 (EGFL7) were significantly correlated with the severity of NVC abnormalities in SSc 
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(104). Patients with the most severe capillary changes and DUs had serum EGFL7 
levels significantly lower than healthy controls, while the EGFL7 levels did not differ 
significantly between controls and SSc patients with less capillary damage and lack of 
DUs. 
   Serum vaspin levels were significantly decreased in SSc patients with DUs 
compared to those without, suggesting the potential contribution of this adipokine 
implicated in vascular inflammation and remodeling (105). 
   In a study analyzing the correlation between serum levels of uric acid and some 
clinical variables of SSc, the mean value of uric acid increased with the severity of NVC 
damage (106). 
   Identification of biomarkers of future disease remains the next great frontier in SSc, 
as they are keys for proper clinical management and for selecting patients for drug 
trials (94). Patients with RP without an established connective tissue disease were 
studied at their first evaluation, to correlate the levels of endothelial markers with the 
subsequent development of an overt disease (107). Plasma levels of tissue-type 
plasminogen activator (t-PA), vWF and IL-6 were higher in patients with normal NVC 
than in healthy controls and even much higher in patients with NVC scleroderma 
pattern. After 36 months, among 48 RP patients with normal basal NVC, 24 were 
diagnosed as primary and 24 as secondary RP. In secondary RP, basal levels of t-PA, 
IL-6 and particularly vWF were higher than in primary RP and healthy controls. Further 
larger, multicenter, prospective, longitudinal studies will be needed to identify and 
validate critical biomarkers of SSc (94). 
 
 
3.2 Loss of angiogenesis in Systemic Sclerosis: paradox or myth? [Doc. 1] 
 
   Angiogenesis is a complex and finely balanced process of formation of new vessels 
from the pre-existing ones, mainly triggered by tissue hypoxia. Sprouting angiogenesis 
encompasses an increase in vasopermeability, leading to the extravasation of plasma 
proteins that function as a temporary scaffold for migrating ECs. Matrix 
metalloproteinases, secreted by the endothelium, break down the vascular basement 
membrane and allow the invasion of the surrounding stroma by ECs, in the direction 
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of the pro-angiogenic stimulus. ECs migration and invasion are accompanied by 
proliferation and the organization of newly formed ECs into three-dimensional tubular 
structures. Lumen formation and vessel wall stabilization by pericytes are the final 
processes of sprouting angiogenesis and lead to the formation of a functional network 
of new capillary vessels (108).  
   Physiological angiogenesis is tightly regulated by the opposing activities of 
stimulating (pro-angiogenic) and inhibiting (anti-angiogenic) factors (109). VEGF is a 
central regulatory factor, which controls several cellular and molecular steps in the 
angiogenic cascade. Indeed, under VEGF priming, ECs increase their migration and 
initiate the proliferative process which will stop only when a complete tube structure 
will be formed (110). Under normal conditions, the levels of angiogenesis inducers and 
inhibitors are balanced and angiogenesis does not occur in healthy tissues (111). If 
their activity becomes altered under pathological conditions, abnormal growth of the 
vasculature and defective repair processes may occur (109). 
   Defective angiogenic pathways have been identified in SSc patients and several 
mechanisms have been implicated (Figure 5) (108): 
- a defective contribution of SSc immune cells to angiogenesis; 
- a severe imbalance between pro-angiogenic and anti-angiogenic factors in SSc; 
- platelet activation, aggregation and release of bioactive molecules into the 
circulation and injured endothelium; 
- overexpression of pro-angiogenic transcripts and a variety of genes with negative 
effect on angiogenesis by SSc MVECs; 
- a change in the endothelial phenotype of residual microvessels, favoring anti-
angiogenic mechanisms. 
   Existing studies point to the presence of intrinsic pro-angiogenic factors residing in 
SSc vasculature and adjacent tissues. The inability to regenerate injured vessels might 
result from the failure of subsequent stages of angiogenesis, such as lumen formation 
or vessel maturation or stabilization. Alternatively, persistent injury may interfere with 
this process (112). 
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Figure 5 – Potential mechanisms of deregulated angiogenesis in SSc. Adapted from (Rabquer BJ, Koch 
AE. 2012.) (113). bFGF – basic fibroblast growth factor; Fli1 – Friend leukemia integration1; JAM-A – junctional 
adhesion molecule-A; MMP-12 – matrix metalloproteinase-12; SDF-1 – stromal cell-derived factor 1; uPAR – 
urokinase plasminogen activator receptor; VEGF – vascular endothelial growth; VEGFR-2 – VEGF receptor 2. 
 
 
   Whether deregulated levels of circulating angiogenic factors or angiostatic factors (or 
both) are a cause or a consequence of an ongoing vascular disease is presently 
unknown (112). 
   In a recent study, dermal MVECs isolated from SSc patients were unable to respond 
to pro-angiogenic chemokines, despite their increased expression in serum and ECs 
(114). The signaling pathways and transcription factor machinery activated by 
chemokines are impaired in SSc ECs. 
 
The significance of “time” 
   Although most studies point to a lack of angiogenesis in SSc, it does not correspond 
to the whole truth during SSc evolution. 
   In the early stage of the disease, a pro-inflammatory state and an increased 
production of pro-angiogenic factors may stimulate angiogenesis. Capillaroscopic 
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analysis of the nailfold beds demonstrates the presence of tortuous, giant capillary loop 
clusters that are surrounded by normal capillary loops of varied shapes, with some 
detectable micro-hemorrhages, reminiscent of immature and unstable newly formed 
microvessels, during an uncontrolled angiogenic response (108, 115).  
   This short pro-angiogenic response is followed by an extensive reduction in capillary 
density, leaving large avascular areas. The dramatic switch from pro- to anti-
angiogenic characteristics suggests an impairment of the angiogenic process which 
might in part be explained by the action of several angiostatic factors (VEGF165b, 
angiopoietin-2), ultimately resulting in profound loss of capillaries along with the 
absence of visible new normal vessel formation (108, 115, 116). An alternative 
explanation for the loss of angiogenesis in the course of SSc is that the upregulated 
pro-angiogenic factors could be exceeded by an even greater upregulation of 
angiostatic factors (108).  
   Cumulative data support an initial VEGF-related pro-angiogenic event in SSc 
patients but suggest that the angiogenic process is then aborted (115). As disease 
progresses, a marked loss of the microvasculature occurs in several organs. The 
reduction in capillaries leads to a decrease in the supply of oxygen and nutrients and 
thus to a hypoxic state. Tissue hypoxia is normally a trigger for angiogenesis; however, 
vascular recovery is impaired in SSc, and avascular areas are prominent (113). 
   The severity of microvascular damage is sequential (112), as testified by 
morphological changes in NVC (capillary enlargement followed by aberrant capillary 
shapes and then by capillary loss) and is paralleled by a different activity of vascular 
mediators through disease progression over time. Indeed, in SSc, the meaning of 
“time” in disease evolution is determined by its severity and activity, instead of 
measured by the years from diagnosis (Figure 6). The associations between speciﬁc 
NVC patterns and severe internal organ involvement represent a shift in interest from 
the diagnostic to the prognostic utility of NVC in SSc (117). 
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Figure 6 – The significance of “time” in systemic sclerosis. 
 
   Defective angiogenesis, due to a combination of several pathological mechanisms, 
accompanies SSc evolution and ranges from an early pro-angiogenic state to a late 
impairment of the angiogenic process, ultimately resulting in reduced capillary density 
and extensive avascular areas. 
   In vitro effects on dermal MVECs from sera of patients treated with intravenous 
cyclophosphamide (CYC) or sera of treatment-naïve patients have been studied (118). 
When dermal MVECs were challenged with sera from CYC-treated SSc patients, their 
angiogenic capacity was comparable to that of cells treated with healthy sera, while 
wound healing capacity and chemotaxis did not show significant differences between 
CYC-treated and treatment-naïve sera. Contrarily to treatment-naïve sera, MVECs 
proliferation was not impaired in the presence of sera from CYC-treated patients and 
CYC-treated SSc sera did not induce MVECs apoptosis. The authors concluded that 
CYC treatment might boost angiogenesis and consequently improve peripheral 
microangiopathy.  
   Recognizing the different phases of angiogenic response in SSc is essential, as the 
complex imbalance between pro-angiogenic and angiostatic factors might be a 
therapeutic target. In this regard, strategies for dosing and timing of angiogenic factors 
might be of major relevance. 
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3.3 The VEGF Family and its co-receptors Neuropilins 
 
  Among the most potent pro-angiogenic cytokine families is the VEGF family, which 
includes VEGF-A to D and placental growth factor (PlGF) (119). VEGF-A is 
alternatively spliced to generate VEGF-A121, VEGF-A145, VEGF-A165 and VEGF-A189 
(its main isoforms), which are endowed with different biological properties (120). 
   VEGFs are master regulators of vascular development and of blood and lymphatic 
vessel function, during health and disease, in adults. These ligands act through three 
tyrosine kinases receptors (VEGFR-1 to -3), that dimerize and become activated upon 
ligand-binding (121, 122). VEGFR-1 is critical in the regulation of migration of 
endothelial precursors as well as mature monocyte/macrophages; VEGFR-2 is the key 
transducer of VEGF function in vascular ECs; and VEGFR-3 is required for lymphatic 
endothelial function. The active VEGF receptors (VEGFRs) initiate signal transduction 
pathways. Signaling is modulated through co-receptors such as heparan sulfate, 
neuropilins (NRPs) and integrins. Importantly, angiogenic signaling is accomplished 
only through the coordinated activity of VEGF, VEGFR and NRP. While binding of 
VEGF to VEGFR weakly activates its intracellular kinase activity, NRP is required for 
strong and sustained kinase activation, leading to the initiation of the pro-angiogenic 
cascade (119, 120, 122) (Figure 7).  
   VEGF-A-induced VEGFR-2 homodimerization and consequent kinase activation is 
assumed to underlie most of the known VEGF biology in vascular ECs. VEGFR-2 is 
critical for vascular development, as gene inactivation of Vegfr2 results in early 
embryonic lethality (122). VEGFR-2 plays essential roles not only in endothelial 
differentiation/proliferation and vascular permeability but also in a wide range of other 
ECs activities, such as survival and motility. 
   VEGF-A is secreted by a variety of cells and acts in a paracrine manner on ECs to 
stimulate signal transduction and regulate cellular function. Additionally, endothelial 
secretion of VEGF-A is essential for promoting cell survival in an autocrine manner 
(123). VEGF is produced as a consequence of relative hypoxia in a growing tissue and 
mediates angiogenesis mainly through VEGFR-2 and NRP1 (120). 
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Figure 7 – VEGF family. (a) VEGF-A splice isoforms indicating the exon-based origin of the domain 
organization. (b) VEGF proteins are disulphide-crosslinked (red) antiparallel homodimers, indicated here 
for VEGF-A. (c) Outline domain structure of VEGFR and NRP isoforms, drawn as transmembrane 
monomers (left). Representation (right) illustrating how VEGF-A165 might crosslink VEGFR-2 and NRP1 
to effect signaling. Adapted from (Djordjevic S, Driscoll PC. 2013.) (124). 
 
 
   VEGF-A binding to VEGFR-2 triggers dimerization and trans-autophosphorylation of 
several cytoplasmic tyrosine residues. VEGFR-2 activation initiates downstream 
intracellular signaling events, such as p38 mitogen-activated protein kinase (involved 
in controlling cytoskeletal dynamics, actin remodeling and ECs migration), extracellular 
signal-regulated kinases 1/2 with subsequent activating of transcription factor 2 
(determining regulation of cell proliferation, migration, tubulogenesis and ECs-
leukocyte adhesion) and phosphoinositide-3-kinase with sequential activation of Akt 
and endothelial nitric oxide synthase (causing increased cell survival and nitric oxide-
induced vascular permeability). Increased VEGFR-1 expression and calcium-
regulated plasma membrane translocation upon VEGF-A mediated VEGFR-2 
activation constitutes a negative feedback loop (123). 
   VEGF dysfunction is implicated in pathological angiogenesis, leading to major 
chronic disease states including atherosclerosis, diabetes and cancer. In addition to 
directly regulating pro-angiogenic signal transduction pathways and subsequent gene 
expression, VEGFR activation influences metabolic homeostasis and plays essential 
roles in non-vascular systems, such as the immune system, epithelium and brain (123). 
In rheumatoid arthritis (RA), VEGF and angiopoietins are the most potent pro-
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angiogenic molecules promoting synovial angiogenesis, an early and critical event in 
disease pathogenesis (125). Moreover, VEGF genetic polymorphisms as well as 
VEGF levels may be associated with the susceptibility to RA (126). In systemic lupus 
erythematosus, serum levels of VEGF were higher than in controls, significantly 
different according to disease activity degree and directly inter-related to abnormal 
NVC patterns and a more active disease (127). 
   The spectrum of cell types and tissues susceptible to regulation by VEGFs and 
VEGFRs highlights their therapeutic potential (123). Increased insights into VEGF 
signaling may allow the development of drugs that specifically inhibit certain signal 
transduction pathways, responsible for malfunctioning blood and lymphatic vessels in 
disease, while preserving vessel survival (122). 
    
   The NRP family consists of essential multifunctional vertebrate cell surface 
receptors, functioning in many key biological processes including in the cardiovascular, 
neuronal and immune systems (128). 
   NRPs were initially characterized as receptors for class 3 semaphorins (Sema3) 
family, functioning in axon guidance. NRPs have also been shown to be critical for 
VEGF-dependent angiogenesis. Intriguingly, NRP function in these seemingly 
divergent pathways is critically determined by ligand-mediated cross-talk, which 
underlies NRP function in both physiological and pathological processes. Multiple 
general mechanisms have been found to directly contribute to the pleiotropic function 
of NRP (119) (Figure 8). Global NRP1 deletion results in embryonic lethality and 
severe neuronal and cardiovascular defects (129). 
   There are two conserved NRP members in vertebrates: NRP1 and NRP2. The NRPs 
similarly consist of a large extracellular domain, one transmembrane domain and a 
relatively short cytoplasmic tail. The extracellular domains of both NRPs are divided 
further into the a1–a2 subdomain, which binds semaphorins; the b1–b2 subdomain, 
which binds VEGF and supports semaphorin binding to the a1–a2 subdomain; the c 
subdomain is dispensable for ligand binding but essential for ligand-dependent 
signaling and mediates NRP dimerization, together with the transmembrane domain 
(119, 120). 
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   NRP1 was initially identiﬁed as a VEGF-A165 splice form speciﬁc receptor but it has 
recently been demonstrated that NRP1 can also bind other VEGF-A isoforms, yet 
uniquely and speciﬁcally physically engages VEGF-A165 (119). In particular, NRP1 has 
been shown to be essential in VEGF-A-induced vessel sprouting and branching (120). 
   NRP1 binds VEGF with an approximately three-fold higher affinity than VEGFR-2. 
Furthermore, NPR1 additionally binds PlGF and VEGF-B, whereas NRP2 binds PlGF, 
VEGF-A and VEGF-C. NRPs interact with different receptors: NRP1 is a co-receptor 
for VEGFR-1 and 2, whereas NRP2 is a co-receptor for VEGFR-3. Soluble NRPs 
function as natural inhibitors, with sNRP1 acting as a competitive antagonist of 
VEGF165 (130). It remains to be shown whether NRP1 transduces VEGF signals 
independently of VEGFR-2 or whether it modulates VEGFR-2 signaling (120).  
 
Figure 8 – Neuropilin (Nrp) structure and hypothetical model of interaction with multiple growth factors. 
Adapted from (Prud'homme GJ, Glinka Y. 2012.) (131). 
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      NRP is emerging as a multifaceted vascular regulator. In the vasculature, NRP1 is 
expressed by ECs, vSMCs, pro-angiogenic tissue macrophages and vascular 
precursor mesenchymal stem cells, controlling several signaling pathways critical for 
blood vessel development and function (129).  
   Besides its role as VEGF co-receptor in ECs, NRP1 has been linked to multiple 
VEGF-independent vascular signaling pathways, including those driven by fibroblast 
growth factor, TGF-β and PDGF (132). NRP1 promotes angiogenic sprouting either by 
amplifying VEGFR-2 signaling in tip cells and by inhibiting TGF-β signaling in stalk 
cells. On the other hand, NRP1 can promote PDGF signaling and PDGF-dependent 
migration and proliferation of vSMCs (129). 
 
   Semaphorins are grouped into eight classes based on their structural domains; they 
are characterized by an amino-terminal Sema domain, essential for signaling, and can 
play a repulsive or attractive role depending on the cell types and biological context. 
Sema3 family exerts chemorepulsive and anti-angiogenic activity in ECs. All Sema3 
proteins (except Sema3E) signal through two major receptor families, Plexins and 
NRPs, by forming a holoreceptor complex consisting of NRPs as ligand binding, and 
Plexins as signal transducing subunit (133). 
  Sema3 can directly compete with VEGF-A for their shared C-terminal arginine binding 
pocket in the NRP b1 subdomain, inhibiting VEGF-induced ECs proliferation and 
migration (Figure 9). 
 
Figure 9 – Crosstalk between NRP ligands. Adapted from (Parker MW et al. 2012.) (119). 
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   Sema3A and F also inﬂuence vascular development and angiogenesis by inhibiting 
integrin-mediated adhesion of ECs to the ECM and enabling the de-adhesion required 
for vascular remodeling and also by inducing ECs apoptosis (130). The interplay of 
VEGF and Sema3 is important for diseases associated with angiogenesis (119). Furin 
processing of Sema3 family members has been demonstrated to be critical for potent 
and selective engagement of the NRP1 b1 domain, which is critical for competitive 
binding with VEGF (128). 
   Sema4A (which also binds to NRP1) and Sema4D were the ﬁrst semaphorin family 
members found to be expressed on immune cells. These semaphorins appear to play 
critical roles in diverse physiological and pathological processes, namely in the 
pathogenesis of autoimmune diseases (rheumatoid arthritis and systemic lupus 
erythematosus), which makes them molecules of interest for a potential 
immunotherapy (134). 
 
The VEGF Family in Systemic Sclerosis 
   VEGF is strongly overexpressed in the skin and sera of SSc patients, by unclear 
mechanisms, and its receptors (VEGFR-1 and -2) are upregulated, although non-
compensative new vessel formation is observed. Moreover, serum levels of VEGF 
signiﬁcantly correlate with the development of SSc digital ulcers (DUs) and higher 
levels appear to be protective. VEGF shows higher levels mainly at the earliest stages 
of the disease, which may be related to compensatory mechanisms (135-137).  
   Prolonged overexpression of VEGF might have deleterious effects on the vascular 
network, while very high concentrations of pro-angiogenic VEGF isoforms are needed 
to overcome the inhibitory effects of anti-angiogenic factors (24). Serum levels of 
VEGF were inversely correlated with NVC capillary density (138) and higher levels of 
VEGF were reported to be independently associated with “late” NVC pattern and 
history of DUs (139). High VEGF levels might serve as a surrogate marker of capillary 
damage in SSc (138). 
   Patients without DUs were found to have higher serum levels of VEGF than patients 
with DUs (140, 141) and VEGF appeared to be protective against ischemic 
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manifestations, when its concentrations exceeded a certain threshold level (140). High 
serum levels of VEGF did not predict new DUs (142). 
   The paradox of VEGF overexpression in SSc despite clear evidence of an insufficient 
angiogenesis has lately gained new insights. VEGF-A pro-angiogenic (VEGF-A165) and 
anti-angiogenic (VEGF-A165b) isoforms have been uncovered and appear to be 
generated by alternative splicing mechanisms in the terminal exon of VEGF pre-
messenger RNA. A switch from pro-angiogenic to anti-angiogenic VEGF-A isoforms 
appears to play a crucial role in the defective angiogenic and vascular repair processes 
that characterize SSc (143-145). 
   VEGF165b appears selectively overexpressed in different cell types of SSc dermis 
and SSc dermal MVECs express and release elevated levels of VEGF165b (143). 
Additionally, increased plasma levels of the VEGF165b are associated with the severity 
of nailfold capillary loss in SSc (146). A recent study assessed the contribution of SSc 
platelet-derived factors to the angiogenesis of human dermal MVECs (147). In SSc 
platelet releasates, VEGF165b and VEGF165b/VEGF ratio were significantly higher 
versus control subjects. These findings suggest that platelets may be a major source 
of circulating VEGF165b in SSc, following their activation on contact with the injured 
endothelium (145).    
   Urokinase-type plasminogen activator receptor (uPAR) has been assumed as 
another player involved in SSc pathogenesis. Its interaction with VEGFR-2 is 
determinant for VEGFR-2 pro-angiogenic signaling in ECs and VEGF-A-induced 
angiogenesis is prevented in uPAR-deficient mice (148, 149). uPAR 
inactivation/deficiency may significantly contribute to VEGF-A/VEGFR-2 system 
abnormalities in SSc (145). 
    In an avian-model of SSc, ischemic skin lesions treated locally with VEGF121-ﬁbrin 
showed clinical improvement versus ﬁbrin treated controls, suggesting that cell-
demanded release of VEGF121 from ﬁbrin matrix induces controlled angiogenesis by 
differential regulation of VEGFR-1 and VEGFR-2 expression, shifting the balance 
towards the pro-angiogenic VEGFR-2 (150). 
   VEGF may also represent a molecular link between vascular involvement and 
fibrosis (9). VEGF+/+, but not VEGF+/- transgenic mice, spontaneously developed 
significant skin fibrosis, indicating the profibrotic effect of VEGF in a gene-dosing 
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manner, highlighting the links between TGFβ and VEGF pathways (151). Moreover, a 
higher number of microvessels was observed in VEGF+/- transgenic mice than in 
VEGF+/+ transgenic mice, reinforcing the possible involvement of VEGF in the 
perturbation of angiogenesis secondary to fibrosis. Indeed, inhibition of VEGF with 
bevacizumab prevented the bleomycin-induced dermal fibrosis in mice (152), 
reinforcing a causative role of VEGF in SSc pathogenesis. 
 
The Neuropilin Family and the Semaphorin Family in Systemic Sclerosis 
   Besides its role in VEGF-mediated angiogenesis, NRP is now known to bind to 
members of the ﬁbroblast growth factor family, galectin-1, hepatocyte growth 
factor/scatter factor, anti-thrombin III, prion protein, TGF-β1 and PDGF. It has been 
found that VEGF and NRP1 directly promote epithelial-mesenchymal transition. A role 
for NRP in ﬁbrosis has also been proposed, with NRP1 found to regulate TGF-β1 and 
PDGF signaling (129, 130). 
   Accumulating evidence indicates that semaphorins and NRPs have distinct biological 
activities in various phases of immune responses, from immune initiation to terminal 
inﬂammatory immune responses (153). They have been studied in systemic lupus 
erythematosus (154, 155), rheumatoid arthritis (156) and Sjögren syndrome (157) but, 
to date of project writing, there was no published data about NRP expression in SSc. 
Considering its link to both VEGF and TGF-β cascades, which are key players in SSc 
pathogenesis, respectively in vasculopathy and fibrosis, a causative role of NRP1 in 
SSc was meant to be explored. 
   More recently, the unique member of Sema3 family that binds and signals directly 
through Plexin-D1, independently of NRPs (Sema3E) has been investigated in SSc 
(158). Serum Sema3E levels were found to be higher both in primary RP subjects and 
SSc patients than in controls, and higher levels correlated with “early” NVC pattern and 
the absence of digital ulcers. Sema3E expression was strongly increased in SSc 
dermal microvascular endothelium and cultured SSc-MVECs showed higher levels of 
phosphorylated Plexin-D1 and Sema3E expression than healthy MVECs. Stimulation 
with SSc sera increased phosphorylated Plexin-D1 and Sema3E in healthy 
microvascular endothelial cells (H-MVECs) and the addition of Sema3E-binding 
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Plexin-D1 soluble peptide significantly attenuated the antiangiogenic effect of SSc sera 
on H-MVECs. 
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III. AIMS 
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   According to the research gap identified in the Introduction, the meaning of this 
project has been to: 
• Explore further explanations for deregulated angiogenesis in SSc; 
• Lift the curtain of the neurovascular interactions in SSc; 
• Discover the “vascular environment” in patients with VEDOSS; 
• Improve knowledge on the molecular and cellular pathways that contribute to 
SSc vasculopathy, so that, in the future, specific therapies for reversing vascular 
injury or direct normal vascular repair can be developed. 
 
The specific objectives of this thesis were to: 
• Study the possible involvement of the axis NRP1/Sema3A in the pathogenesis of 
SSc, by investigating whether the levels of NRP1 and Sema3A could be altered in 
the circulation, skin and ECs of patients with VEDOSS and SSc, as well as the 
mechanism explaining the deregulated expression of these molecules and their 
possible contribution to the disturbed angiogenesis of SSc; 
• Investigate whether patients with VEDOSS may already present circulating 
markers and in vitro signs of microvascular dysfunction. 
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IV. METHODS 
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1. Chronogram of the Activities 
 
   The chronogram of the activities developed during the PhD Program is presented in 
Table 4. 
 
Table 4 – Chronogram of PhD Activities. 
 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 
2011  PhD Lectures 
2012 PhD Lectures Project writing/ submission... 
2013 …Ethical approval 
Applying to Grants 
Requiring Residency interruption 
Working in… 
First Article Writing 
2014 …Florence 
Interview 
Meeting 
Working in Porto  
Second Article writing 
2015 
Working in Porto 
Fourth Article writing 
2016 Third Article writing  Thesis… 
2017 …writing  
 
 
 
2. Study Design and Participants 
 
   This was a cross-sectional study, recruiting patients followed regularly at two centers:  
I. Department of Experimental and Clinical Medicine, Division of Rheumatology, 
Azienda Ospedaliero-Universitaria Careggi (AOUC), Florence, Italy; 
II. Autoimmunity Outpatient Clinic of the Department of Internal Medicine, Centro 
Hospitalar de São João (CHSJ), Porto, Portugal. 
   Table 5 summarizes the inclusion and exclusion criteria of the subjects, according 
to the three groups of participants: 1) SSc patients, 2) VEDOSS patients and 3) Healthy 
controls. 
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Table 5 – Inclusion and exclusion criteria for study participants. 
 SSc patients  VEDOSS patients Healthy controls 
Inclusion 
criteria 
Presence of both: 
• Score ≥9 in 2013 
ACR/EULAR 
classification criteria 
for SSc 
• Well-defined clinical 
subset (limited 
cutaneous/diffuse 
cutaneous SSc) 
 
 
Presence of all three: 
• RP 
• Puffy fingers/ sclerodactyly 
• Positive ANA 
And ≥1 of: 
• NVC with SSc pattern 
• Positive SSc-specific 
antibodies 
(anticentromere, anti-
topoisomerase I, anti-RNA 
polymerase III) 
Plus 
• Score <9 in 2013 
ACR/EULAR classification 
criteria for SSc 
• Age, race and 
gender-matched 
subjects 
 
• Written informed consent for chart review and for performing blood tests (and skin 
biopsy when appropriate) 
• Clinical information available for chart review  
Exclusion 
criteria 
• Presence of another concomitant autoimmune disease • Presence of any 
autoimmune 
disease  
• Primary RP 
 • Any internal organ 
involvement due to SSc 
 
• Inability to give written informed consent 
ACR – American College of Rheumatology; ANA – antinuclear antibodies; EULAR – European League Against 
Rheumatism; NVC – nailfold videocapillaroscopy; RP – Raynaud’s phenomenon; SSc – systemic sclerosis; 
VEDOSS – very early diagnosis of systemic sclerosis. 
 
    
   The variables of clinical information obtained by chart review are presented in the 
Appendix section of this document [Doc. 2]. 
   The global characterization of patients included is presented in Table 6.  
   In SSc group, 49 patients were from Florence and six from Porto. In VEDOSS group, 
all the patients included were from Florence. We included 55 age-matched and sex-
matched healthy individuals (51 women; median age 52 years, range 29 to 70 years). 
   For late-outgrowth endothelial progenitor cell-derived ECs, peripheral blood was also 
collected from 15 SSc patients (13 women; n=9 with lcSSc and n=6 with dcSSc; 
median age 60 years, range 42 to 78 years) and eight healthy individuals (all women; 
median age 55 years, range 30 to 65 years), at Cochin Hospital, Paris, France. 
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Table 6 – Demographic and clinical characteristics of the patients with SSc and VEDOSS included for 
collection of serum samples. 
 SSc patients 
(n=55) 
VEDOSS patients 
(n=25) 
Demographic 
Age, years, median (range) 64 (37-81) 50 (19-77) 
Gender 
     Male 
     Female 
 
6 (11) 
49 (89) 
 
4 (16) 
21 (84) 
Race 
     Caucasian 
     Asian 
 
54 (98) 
1 (2) 
 
25 
- 
Disease duration, years, median (range)a 10 (1 to 31) 1 (0 to 8) 
Clinical manifestations (ever before) 
Disease subset 
     lcSSc 
     dcSSc 
 
38 (69) 
17 (31) 
 
- 
- 
Puffy fingers 47 (85) 11 (44) 
Sclerodactyly 50 (91) - 
Digital ulcers 32 (58) 1 (4) 
Digital tip pitting scars 16 (29) 1 (4) 
Telangiectasia 18 (32) - 
Arthritis 10 (18) 1 (4) 
Pulmonary arterial hypertensionb 5 (9) - 
Interstitial lung diseasec 33 (60) - 
Gastrointestinal involvementd 36 (65) 6 (24) 
Cardiac involvemente 13 (24) - 
Renal involvementf 19 (35) - 
Clinical manifestations (at the time of blood withdrawal) 
Digital ulcers 6 (11) - 
Modified Rodnan Skin Score, median (range) 6 (0-35) 0 (0-4) 
Autoantibodies 
Antinuclear 
Anticentromere 
Anti-topoisomerase I 
Anti-RNA polymerase III 
Anti-PM/Scl 
55 (100) 
32 (58) 
17 (31) 
- 
2 (36) 
25 
11 (44) 
6 (56) 
- 
1 (4) 
Other laboratory exams 
Erythrocyte sedimentation rate, average±SD 22±17 12±10 
Hypocomplementemia (C3 or C4) 1 (2) 1 (4) 
Elevated creatin kinase 3 (5) 1 (4) 
Nailfold videocapillaroscopy pattern 
     Normal 
     “Early” 
     “Active” 
     “Late” 
4 (8) 
11 (18) 
23 (47) 
17 (27) 
7 (28) 
13 (52) 
5 (20) 
0 
2013 ACR/EULAR score, median (range) 14 (10-28) 7 (7-8) 
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Table 6 – (cont.). 
 SSc patients 
(n=55) 
VEDOSS patients 
(n=25) 
Therapy 
Corticosteroids, n (average current daily dose of 
prednisolone-equivalent, mg) 
6 (4) - 
Angiotensin-converting enzyme inhibitors/ ARB  15 (27) - 
Calcium channel blockers 13 (24) 5 (20) 
Prostacyclin analogs (ever before) 42 (76) 1 (4) 
Endothelin antagonists (ever before) 8 (15) - 
Phosphodiesterase inhibitors (ever before) 9 (16) 2 (8) 
Immunosuppressants (ever before) 39 (71) - 
 
Except where indicated otherwise, values are the number (%) of subjects.  
aDisease duration was calculated since the first non-Raynaud’s symptom of SSc. 
bDiagnosed by right-sided heart catheterization according to standard definitions. 
cDetermined by thoracic high-resolution computer tomography. 
dEvidence of esophageal hypomotility, incompetence of the lower esophageal sphincter, gastric antral vascular 
ectasia, pseudo-obstruction, bacterial small bowel overgrowth with malabsorption, fecal incontinence. 
ePericardial involvement, myocardial fibrosis, diastolic dysfunction, conduction disturbances, arrhythmias non-
attributable to other causes. 
fHistory of SSc renal crisis and/or evidence of microalbuminuria and/or elevation in plasma creatinine non-
attributable to other causes. 
ACR – American College of Rheumatology; ARB – angiotensin II receptor blockers; dcSSc – diffuse cutaneous 
SSc; EULAR – European League Against Rheumatism; lcSSc – limited cutaneous SSc. 
 
 
3. Data and Samples Collecting 
 
   Patients were provided written information on study design and goals and, when 
intended, signed informed consent. Interview, physical exam with NVC and chart 
review were performed at the evaluation center. Blood samples (and skin biopsies) 
were collected and stored, as specified in Results section. Before blood sampling, 
patients were washed out for ten days from oral vasodilating drugs and for two months 
from intravenous prostanoids. 
 
 
4. Laboratory Assays 
 
   The following assays were performed: 
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• Assessment of serum circulating levels of pan-VEGF, soluble NRP1 (sNRP1) and 
Sema3A in patients with VEDOSS, patients with SSc and healthy controls, by 
sandwich enzyme-linked immunosorbent assay (ELISA). 
 
• Assessment of protein expression of NRP1 and Sema3A in skin biopsies from SSc 
patients and healthy donors, by immunoﬂuorescence and Western blot. 
 
• Measurement of the expression of NRP1 in H-MVECs, at basal condition and after 
stimulation with recombinant human VEGF-A165, VEDOSS sera, SSc sera and 
healthy controls sera, by Western blot. NRP1 protein expression was also evaluated 
at basal level in dermal MVECs from SSc patients and in late-outgrowth endothelial 
progenitor cell(EPC)-derived ECs from SSc patients and healthy controls, by 
Western blot. 
 
• Evaluation of Fli1 protein expression in H-MVECs and late-outgrowth EPC-derived 
ECs from patients with SSc and healthy controls, by Western blot. Assessment of 
the effect of Fli1 gene silencing on mRNA levels of the NRP1 gene in H-MVECs 
transfected with Fli1 siRNA or non-silencing scrambled RNA, by quantitative real-
time protein chain reaction (PCR). Evaluation of the binding of Fli1 to NRP1 gene 
promoter by chromatin immunoprecipitation. 
 
• Assessment of in vitro capillary morphogenesis in dermal MVECs from SSc 
patients and in H-MVECS incubated with sera from VEDOSS patients, SSc patients 
and healthy controls, by Matrigel assay. 
 
• Assessment of the ability of cell proliferation in H-MVECs stimulated with VEDOSS 
sera, SSc sera and healthy controls sera, by 5’-bromodeoxyuridine (BrdU) assay. 
 
• Evaluation of the capacity of cell migration to an injured spot in H-MVECs 
stimulated with VEDOSS sera, SSc sera and healthy controls sera, by wound-
healing assay. 
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   A comprehensive description of these assays is included in the Methods section of 
Second Paper and Third Paper. 
 
 
5. Statistical Analysis 
 
   Clinical correlations and statistical analysis were performed with Statistical Package 
for Social Sciences (SPSS) software for Windows, version 20.0 (SPSS, Chicago, IL, 
USA). 
 
 
6. Ethical Approval 
 
   The study was approved by the local institutional review board of AOUC, Florence, 
Italy (AOUC 69/13), as well as by the Health Ethical Committee of CHSJ, Porto, 
Portugal (CHSJ 84/13) – the approval letters are accessible in the Appendix section 
of this document [Doc. 3 and 4]. The study was also approved by the local institutional 
review board at the Cochin Hospital, Paris, France. All subjects provided written 
informed consent. 
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VI. GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Paul Klee. The Light and So Much Else (1931). 
106 
 
 
  
107 | General Discussion 
 
Microvasculopathy of Systemic Sclerosis is present from the (Very Early) onset 
   The vascular hypothesis for SSc was introduced by Campbell and LeRoy, in 1975 
(159). The authors proposed that SSc manifestations were due to vascular lesions 
developed at varying rates and degrees across multiple organs. A cascade of events, 
including deregulated inﬂammatory responses and persistent activation of ﬁbroblasts, 
would lead to decreased blood ﬂow and eventual ﬁbrosis of involved organs. 
   Several decades after, compelling clinical and biologic evidence still suggests that 
blood vessels constitute the primary target for both initiating and propagating SSc 
(116). Some environmental factors may injure ECs, triggering aberrant inflammation 
and vascular remodeling, leading to the development of SSc in individuals highly 
predisposed by genetic and epigenetic factors (81). Moreover, despite all the 
treatments currently available, SSc vasculopathy is responsible for the most significant 
disease burdens (digital ulcers, renal failure, PAH), leading to increased morbidity and 
mortality rates in patients with SSc (82). 
   Multiple studies have focused on the possible players involved in SSc vascular 
pathogenesis and numerous cellular and molecular entities have been shown to 
correlate with clinical manifestations of vasculopathy, as revised in the First Paper. 
   Currently, there are no validated biological measurements to assess the subclinical 
vascular activity in patients with SSc and the clinician often does not detect the disease 
until it has already evolved to irreversible fibrotic changes. Searching for new 
biomarkers of very early disease may help screening patients with early 
manifestations, allowing an earlier diagnosis of SSc, and may identify patients at risk 
for major complications, sparing those who are not, from aggressive therapy. 
   The presence of “red flags”, namely RP and puffy fingers, together with abnormal 
NVC and positive SSc-specific autoantibodies, may allow to identify patients with the 
preliminary criteria for VEDOSS (66, 70). These patients already present modifications 
of the microvasculature and complications like digital ulcers (18). 
   To our knowledge and to the date of this project writing, there had been no studies 
exploring VEDOSS vascular “environment”. It would be expectable that recognizing 
which mechanisms are already deregulated in these patients, and comparing with 
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findings at established stage, could assist on further comprehension of SSc from the 
early top of its pathogenic cascade. 
   More recently, patients classified as having undifferentiated connective tissue 
disease at risk for SSc (UCTD/SSc) (75) were shown to have increased levels of 
adhesion molecules, with a gradual increase from UCTD/SSc to fibrotic SSc (160). In 
another study, markers characterizing endothelial dysfunction were found to be 
increased in SSc patients from the earliest stages of disease, when clinical and 
laboratory findings of advanced disease were not yet detected, and linearly increased 
from early to fibrotic SSc (161). 
   In our study, patients classified as VEDOSS already presented circulating 
biomarkers of defective angiogenesis and their sera significantly altered the normal 
behavior of ECs in vitro. After stimulation with VEDOSS sera, the ability of MVECs to 
proliferate and to perform wound-healing was compromised, although in a lesser 
extent than after stimulation with SSc sera. We have also shown a gradual decrease 
in capillarogenesis from VEDOSS to SSc, supporting the progressive antiangiogenic 
features of the disease. 
   According to this evidence, the involvement of the microvascular system and ECs 
injury are in act already in very early SSc, even when only few clinical signs and 
symptoms are present. Rather than having a “pre-disease”, VEDOSS patients display 
characteristics of the established microvasculopathy of SSc, which should immediately 
be targeted. 
   Translating our findings into clinical practice, the relevance of implementing 
VEDOSS criteria is superbly evident, to identify and treat these patients without waiting 
for SSc classification criteria to be met. 
   If clinicians optimize their awareness to VEDOSS “red flags” and send patients to 
reference centers for confirmation, therapeutic measures focusing in controlling 
microvasculopathy can be started much earlier, hopefully postponing the most severe 
complications of SSc. 
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Angiogenesis Paradox Unveiled 
   Microangiopathy in SSc is characterized by a reduced capillary density and an 
irregular chaotic architecture, leading to chronic tissue hypoxia (which is exacerbated 
by ECM accumulation due to fibrosis). Despite the hypoxic conditions (which are 
normally an angiogenic trigger) and the loss of vasculature, there is, paradoxically, no 
evidence for a sufﬁcient compensative angiogenesis: vascular recovery is impaired 
and avascular areas are prominent. This is clearly demonstrated by specific NVC 
morphological changes during disease evolution (113, 135-137). 
    Among the most potent pro-angiogenic cytokine families is the VEGF family, which 
includes master regulators of vascular development and of blood and lymphatic vessel 
function, during health and disease in adults (119). The overexpression of VEGF in 
SSc, while initially assumed as a compensatory mechanism with deleterious effects on 
the vascular network, is currently regarded as consequent of switching from pro-
angiogenic to anti-angiogenic VEGF-A isoforms (143-145).  
   In our study, similarly to SSc patients, VEDOSS patients presented higher serum 
levels of VEGF when compared to healthy controls, with a tendency to higher levels in 
SSc versus VEDOSS. These findings suggest that the normal function of VEGF 
system in angiogenesis is already disturbed in VEDOSS. 
 
Neuropilin 1: widening pathogenic views 
   The neuropilin family of multifunctional cell surface receptors was initially described 
as receptors for Sema3, acting in axon guidance. NRPs are also critical for VEGF-
dependent angiogenesis, in addition to VEGFRs, associating with the ligand–receptor 
signaling complex and modulating the output. Notably, angiogenic signaling is 
accomplished only through the coordinated activity of VEGF, VEGFRs and NRPs, and  
NRP is required for strong and sustained kinase activation, allowing the initiation of the 
pro-angiogenic cascade (119, 120). 
   NRP1 serves as speciﬁc VEGF-A co-receptor on ECs, leading to enhanced migration 
and survival of ECs in vitro (162, 163). NRP1 has been implicated in VEGFR-2-
mediated endothelial permeability and in VEGF-A-induced three dimensional ECs 
biology, such as vessel sprouting and branching (164, 165).  
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    The central role of NRP1 during developmental angiogenesis is exposed by 
knockout mice, which display an embryonic lethal phenotype with severe vascular 
defects, very much resembling the disturbed vessel morphology seen in SSc (166). 
   Despite its coregulation of VEGF and the recognized implication of VEGF system in 
SSc, as well as the more recent link to TGF-β pathway, NRP role had not yet been 
explored in this disease setting.  
   The pathogenesis of RP, a cardinal and very early manifestation of SSc, lays on a 
disturbance of vascular tone, with an abnormal, long-lasting vasoconstriction, in 
response to some stimuli. Any cause inducing functional or structural alterations in 
peripheral nerves, small vessel wall cells and cellular microcirculation may predispose 
to an abnormal vasoconstriction (167). This close interaction between nerves and 
vessels networks, from the very beginning of SSc, made even more appealing to study 
the role of molecules modulating the guidance of both nerves and blood vessels, as 
NRPs. 
   Sema3 family exerts chemorepulsive and anti-angiogenic activity in ECs. Sema3A 
directly competes with VEGF-A for binding to NRP1, inhibiting VEGF-induced ECs 
proliferation and migration (119). Sema3A can also inhibit integrin-mediated adhesion 
of ECs to the ECM, enabling the de-adhesion required for vascular remodeling and 
also by inducing EC apoptosis (130). 
   On these bases, we hypothesized that the axis NRP1/Sema3A could play a role in 
the pathogenesis of SSc-related microvascular abnormalities. 
   In fact, serum levels of NRP1 were signiﬁcantly decreased in patients with SSc 
versus healthy controls and correlated with the severity of SSc-related peripheral 
microvasculopathy. Circulating levels of sNRP1 progressively decreased, reaching the 
lowest values in patients with “active” and “late” NVC patterns. Lower circulating 
sNRP1 levels correlated with the severity of NVC abnormalities and the presence of 
digital ulcers. Of note, the reduction in circulating levels of sNRP1 might be either a 
cause or a consequence of the disease, which is characterized by progressive loss of 
the peripheral microcirculation. 
   Serum levels of sNRP1 were also decreased in VEDOSS patients, when compared 
to healthy controls; however, in contrast to SSc, we found no correlations between 
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serum levels of sNRP1 and NVC patterns, which could be attributable either to the 
smaller number of patients in the VEDOSS group or to a less severe peripheral 
vasculopathy in these patients. Further prospective studies on larger cohorts of 
patients with SSc may elucidate whether circulating levels of sNRP1 could even serve 
as a biomarker reﬂecting the severity and progression of SSc microvasculopathy. 
   While NRP1 expression was constitutively downregulated in SSc dermal MVECs, 
both ex vivo and in vitro, we found no difference in NRP1 protein levels between 
peripheral blood EPC-derived ECs from patients with SSc and healthy controls. 
Accordingly, deregulated expression of this pro-angiogenic receptor appears to be 
confined to the injured microcirculation and not affect bone marrow-derived circulating 
endothelial progenitors. 
   No difference in Sema3A serum levels or expression was found between patients 
and controls, either in SSc and VEDOSS sera and in SSc cutaneous tissue.  
    The expression of NRP1 was signiﬁcantly reduced in H-MVECs after treatment with 
SSc and VEDOSS sera, confirming their anti-angiogenic properties. NRP1 expression 
in H-MVECs was upregulated after stimulation with recombinant VEGF-A165, 
suggesting that its pro-angiogenic effects also lay on upregulating NRP co-receptor. 
The downregulation of NRP1 expression in H-MVECs challenged with SSc and 
VEDOSS patients’ sera supports the evidence that the increased levels of VEGF 
detected in SSc circulation consist mainly on the anti-angiogenic VEGF-A165b isoform. 
   Stimulation of NRP1-silenced H-MVECs with VEGF-A165 and anti-VEGF-A165b 
slightly increased angiogenesis. On the other hand, stimulation of NRP1-silenced H-
MVECs with VEGF-A165b isoform resulted only in a slight decrease in their angiogenic 
capacity. VEGF-A165b isoform is unable to bind NRP-1 and its anti-angiogenic 
properties mostly depend on the inability to recruit VEGFR-2/NRP1 co-receptor 
complex.  
   Numerous studies have previously implicated Fli1 in SSc pathogenesis. Fli1 
expression is markedly suppressed, at least partially, through an epigenetic 
mechanism (168, 169). Recently, a new mouse model, with conditional deletion of the 
transcription factor Fli1 in epithelial cells, recapitulated the disease phenotype 
observed in patients with SSc (44). Fli1 expression was lower in keratinocytes from 
SSc patients compared to healthy individuals and gene silencing of Fli1 in 
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keratinocytes from healthy individuals resulted in a SSc-like gene expression profile. 
Medullary thymic epithelial cells lacking Fli1 showed a reduced expression of 
autoimmune regulator (AIRE) and the authors verified that Fli1 directly regulates AIRE 
transcription. This novel discovery highlights the significant role of Fli1 in autoimmune 
regulation and marks it out as a potentially therapeutic candidate. 
   In our study, Fli1 expression was signiﬁcantly decreased in H-MVECs challenged 
with SSc sera. NRP1 and Fli1 expression was not different between SSc and control 
EPC-derived ECs. Fli1 occupied the NRP1 gene promoter and Fli1 gene silencing 
reduced NRP1 expression in H-MVECs. The signiﬁcant impair in angiogenesis after 
NRP1 gene silencing in H-MVECs was comparable to that of cells treated with SSc 
sera, further supporting the implication of NRP1 deﬁciency in the disturbed 
angiogenesis of SSc. These mechanistic findings allow the assumption of NRP1 as a 
member of the angiogenesis-related gene program regulated by Fli1 in dermal MVECs. 
 
   Figure 10 summarizes the current molecular evidence of the pathogenesis of 
disturbed angiogenesis in SSc.  
   A switch from pro-angiogenic VEGF-A165 to anti-angiogenic VEGF-A165b isoform, 
and concomitant NRP1 co-receptor downregulation due to Fli1 transcription factor 
deficiency, result in an insufﬁcient tyrosine phosphorylation/activation of VEGFR-2 and 
incomplete or transient downstream signaling along with a differential intracellular 
vesicular trafﬁcking of VEGFR-2 towards the degradative pathway, ultimately leading 
to an impaired angiogenic response. Moreover, in SSc ECs, matrix metalloproteinase-
12-mediated cleavage/inactivation of uPAR may further impair the VEGF-A/VEGFR-2 
system. 
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Figure 10 – Current pathogenic views of disturbed angiogenesis in systemic sclerosis. Adapted from 
(Manetti M et al. 2016.) (145). Fli1 – Friend leukemia integration 1; LRP-1 – low-density lipoprotein receptor-
related protein-1; MMP-12 – matrix metalloproteinase-12; NRP1 – neuropilin 1; uPAR – urokinase-type 
plasminogen activator receptor; VEGF – vascular endothelial growth factor; VEGFR – vascular endothelial growth 
factor receptor. 
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   Considerable progresses have been achieved during the last decade for a better 
understanding of the cellular and molecular basis of SSc. Significant abnormalities in 
angiogenesis regulators have been described and may help to explain disrupted 
mechanisms of vascular repair in SSc, with potential implications for improving clinical 
practice. 
   The main findings of this study were: 
• Soluble NRP1 levels were decreased in SSc and VEDOSS; 
• Decreased NRP1 levels were associated with “active” and “late” NVC patterns and 
digital ulcers; 
• NRP1 was signiﬁcantly decreased in SSc-MVECs; 
• Sema3A levels and expression did not differ in SSc and healthy controls; 
• NRP1 expression was signiﬁcantly decreased in H-MVECs challenged with SSc and 
VEDOSS sera, while it was not different in SSc and healthy EPC-derived ECs; 
• Fli1 occupied the NRP1 gene promoter and Fli1 gene silencing reduced NRP1 
expression in H-MVECs; 
• NRP1 gene silencing in H-MVECs resulted in signiﬁcantly impaired angiogenic 
capacity; 
• VEDOSS patients already present circulating biomarkers of defective angiogenesis; 
• VEDOSS sera significantly modify the normal behavior of ECs in vitro, in a minor 
extent than SSc sera. 
 
   In conclusion, NRP1 deﬁciency may be an additional factor in the perturbed VEGF-
A/VEGFR-2 signaling, contributing to peripheral microvasculopathy and defective 
angiogenesis in SSc, evident from the very early stage of the disease. 
 
   The study was limited by the number of subjects. These results need to be replicated 
in other samples and populations, with larger size. Further studies are required to 
identify additional circulating biomarkers of vascular dysfunction in VEDOSS patients. 
There is a need to study these potential SSc biomarkers on a prospective cohort of 
patients, followed longitudinally. 
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   A detailed understanding of SSc pathogenesis from its very early beginning is crucial 
for the development of novel therapeutic tools. The discovery of key molecular targets 
may help to develop new and more effective drugs. Normalization of the angiogenic 
cascade could provide a future therapeutic approach for SSc-related vasculopathy. 
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Document 2 – Clinical information obtained by chart review. 
 
Demographic . Age 
. Gender 
. Race 
Presence of comorbidities  
Disease onset . Date of diagnosis / date of first visit 
. Onset of first non-RP manifestation of the disease 
Clinical manifestations 
(ever before) 
 
. Skin thickening / clinical subset 
. Puffy fingers                        
. Sclerodactyly 
. Digital ulcers/ digital tip pitting scars 
. Telangiectasia 
. Arthritis 
. Pulmonary arterial hypertension 
. Interstitial lung disease 
. Gastrointestinal involvement 
. Cardiac involvement 
. Renal involvement                                                                          
Clinical manifestations 
(at the time of blood withdrawal) 
. Digital tip ulcers 
. Modified Rodnan Skin Score 
Autoantibodies . Antinuclear 
. Anticentromere 
. Anti-topoisomerase I 
. Anti-RNA polymerase III 
. Other 
Other laboratory exams 
(the closest to the date of blood 
withdrawal) 
. Erythrocyte sedimentation rate 
. Hypocomplementemia (C3 or C4) 
. Creatin kinase 
. Proteinuria 
NVC 
(the closest to the date of blood 
withdrawal) 
Normal 
SSc pattern: “Early” / “Active” / “Late” 
Tests / Functions 
(the closest to the date of blood 
withdrawal) 
. Echocardiography 
. Electrocardiogram 
. Chest radiography 
. Thorax HRCT scan 
. Pulmonary function tests 
Therapy . Corticosteroids (daily dose) 
. ACE inhibitors/ ARB 
. Calcium channel blockers 
. Prostacyclin analogs 
. Endothelin antagonists 
. Phosphodiesterase inhibitors 
. Immunosuppressive therapy 
. Others 
ACE – angiotensin-converting enzyme; ARB – angiotensin-receptor blockers; NVC – nailfold 
videocapillaroscopy; RP – Raynaud’s phenomenon. 
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